[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/441,723, filed Jan. 21, 2003.
[0002] Insects and other pests cost farmers billions of dollars annually in crop losses and in the expense of keeping these pests under control. The losses caused by insect pests in agricultural production environments include decreases in crop yield, reduced crop quality, and increased harvesting costs. Insect pests are also a burden to vegetable and fruit growers, to producers of ornamental flowers, and to home gardeners and homeowners.
[0003] Cultivation methods, such as crop rotation and the application of high levels of nitrogen fertilizers, have partially addressed problems caused by agricultural pests. However, various demands on the utilization of farmland restrict the use of crop rotation. In addition, overwintering traits of some insects are disrupting crop rotations in some areas.
[0004] Thus, synthetic chemical insecticides are relied upon most heavily to achieve a sufficient level of control. However, the use of synthetic chemical insecticides has several drawbacks. For example, the use of these chemicals can adversely affect many beneficial insects. Target insects have also developed resistance to some chemical pesticides. Furthermore, rain and improper calibration of insecticide application equipment can result in poor control. The use of insecticides often raises environmental concerns such as contamination of soil and water supplies when not used properly, and residues can also remain on treated fruits and vegetables. Working with some insecticides can also pose hazards to the persons applying them. Stringent new restrictions on the use of pesticides and the elimination of some effective pesticides could limit effective options for controlling damaging and costly pests.
[0005] The replacement of synthetic chemical pesticides, or combination of these agents with biological pesticides, could reduce the levels of toxic chemicals in the environment. Some biological pesticidal agents that are now being used with some success are derived from the soil microbe
[0006] Recombinant DNA-based B.t. products have been produced and approved for use. In addition, with the use of genetic engineering techniques, various approaches for delivering these toxins to agricultural environments are being perfected. These include the use of plants genetically engineered with toxin genes for insect resistance and the use of stabilized intact microbial cells as toxin delivery vehicles. Thus, isolated
[0007] B.t. protein toxins were initially formulated as sprayable insect control agents. A relatively more recent application of B.t. technology has been to isolate and transform plants with genes that encode these toxins. Transgenic plants subsequently produce the toxins, thereby providing insect control. See U.S. Pat. Nos. 5,380,831; 5,567,600; and 5,567,862 to Mycogen Corporation. Transgenic B.t. plants are quite efficacious, and usage is predicted to be high in some crops and areas.
[0008] There are some obstacles to the successful agricultural use of
[0009] Another potential obstacle is the development of resistance to B.t. toxins by insects. The potential for wide-spread use of B.t. plants has caused some concern that resistance management issues may arise more quickly than with traditional sprayable applications. While a number of insects have been selected for resistance to B.t. toxins in the laboratory, only the diamondback moth (
[0010] Resistance management strategies in B.t. transgene plant technology have become of great interest. Several strategies have been suggested for preserving the ability to effectively use
[0011] Thus, there remains a great need for developing additional genes that can be expressed in plants in order to effectively control various insects. In addition to continually trying to discover new B.t. toxins (which is becoming increasingly difficult due to the numerous B.t. toxins that have already been discovered), it would be quite desirable to discover other bacterial sources (distinct from B.t.) that produce toxins that could be used in transgenic plant strategies.
[0012] The relatively more recent efforts to clone insecticidal toxin genes from the
[0013] The expected traits for
[0014] Currently, the bacterial genus
[0015]
[0016]
[0017] It has been difficult to effectively exploit the insecticidal properties of the nematode or its bacterial symbiont. Thus, proteinaceous agents from
[0018] There has been substantial progress in the cloning of genes encoding insecticidal toxins from both
[0019] WO 95/00647 relates to the use of
[0020] Four different toxin complexes (TCs)—Tca, Tcb, Tcc and Tcd—have been identified in
[0021] Genomic libraries of
[0022] As reported in WO 98/08932, protein toxins from the genus
[0023] Bioassays of the Tca toxin complexes revealed them to be highly toxic to first instar tomato hornworms (
[0024] None of the four loci showed overall similarity to any sequences of known function in GenBank. Regions of sequence similarity raised some suggestion that these proteins (TcaC and TccA) may overcome insect immunity by attacking insect hemocytes. R. H. ffrench-Constant and Bowen,
[0025] TcaB, TcbA, and TcdA all show amino acid conservation (˜50% identity), compared with each other, immediately around their predicted protease cleavage sites. This conservation between three different Tc proteins suggests that they may all be processed by the same or similar proteases. TcbA and TcdA also share ˜50% identity overall, as well as a similar predicted pattern of both carboxy- and amino-terminal cleavage. It was postulated that these proteins might thus be homologs (to some degree) of one another. Furthermore, the similar, large size of TcbA and TcdA, and also the fact that both toxins appear to act on the gut of the insect, may suggest similar modes of action. R. H. ffrench-Constant and Bowen,
[0026] Deletion/knock-out studies suggest that products of the tca and ted loci account for the majority of oral toxicity to lepidopterans. Deletion of either of the tca or ted genes greatly reduced oral activity against
[0027] The insect midgut epithelium contains both columnar (structural) and goblet (secretory) cells. Ingestion of tca products by
[0028] WO 99/42589 and U.S. Pat. No. 6,281,413 disclose TC-like ORFs from
[0029] WO 01/11029 and U.S. Pat. No. 6,590,142 B1 disclose nucleotide sequences that encode TcdA and TcbA and have base compositions that have been altered from that of the native genes to make them more similar to plant genes. Also disclosed are transgenic plants that express Toxin A and Toxin B. These references also disclose
[0030] Of the separate toxins isolated from
[0031] While the exact molecular interactions of the TC proteins with each other, and their mechanism(s) of action, are not currently understood, it is known, for example, that the Tca toxin complex of
[0032] U.S. patent application 20020078478 provides nucleotide sequences for two potentiator genes, tcdB2 and tccC2, from the tcd genomic region of
[0033] As indicated in the chart below, TccA has some level of homology with the N terminus of TcdA, and TccB has some level of homology with the C terminus of TcdA. TccA and TccB are much less active on certain test insects than is TcdA. TccA and TccB from Photorhabdus strain W-14 are called “Toxin D.” “Toxin A” (TcdA), “Toxin B” (TcbA), and “Toxin C” (TcaA and TcaB) are also indicated below.
[0034] Furthermore, TcaA has some level of homology with TccA and likewise with the N terminus of TcdA. Still further, TcaB has some level of homology with TccB and likewise with the N terminus of TcdA.
[0035] TccA and TcaA are of a similar size, as are TccB and TcaB. TcdB has a significant level of similarity (both in sequence and size) to TcaC.
strain W-14 Some homology nomenclature to: TcaA Toxin C TccA TcaB TccB TcaC TcdB TcbA Toxin B TccA Toxin D TcdA N terminus TccB TcdA C terminus TccC TcdA Toxin A TccA + TccB TcdB TcaC
[0036] Relatively more recent cloning efforts in
[0037] The finding of somewhat similar, toxin-encoding loci in these two different bacteria is interesting in terms of the possible origins of these virulence genes. The
[0038] There are five typical
[0039] TC proteins and genes have more recently been described from other insect-associated bacteria such as
[0040] Bacteria of the genus
[0041] A crystal protein, Cry18, has been identified in strains of
[0042] Although some Identity to Identity to Xwi XptA1 44% 46% Xwi XptA2 41% 41%
[0043] (For a more complete review, see, e.g., Morgan et al., “Sequence Analysis of Insecticidal Genes from
[0044] While
[0045] The subject invention relates to the surprising discovery that toxin complex (TC) proteins, obtainable from organisms such as
[0046] In particularly preferred embodiments of the subject invention, the toxicity of a “stand-alone” TC protein (from
[0047] Stated another way, the subject invention relates to the discovery that
[0048] Certain preferred combinations of heterologous TC proteins are also disclosed herein.
[0049] Many objects, advantages, and features of the subject invention will be apparent to one skilled in the art having the benefit of the subject disclosure.
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057] SEQ ID NO:1 is the N-terminus of Toxin
[0058] SEQ ID NO:2 is an internal peptide of Toxin
[0059] SEQ ID NO:3 is an internal peptide of Toxin
[0060] SEQ ID NO:4 is an internal peptide of Toxin
[0061] SEQ ID NO:5 is an internal peptide of Toxin
[0062] SEQ ID NO:6 is the pDAB2097 cosmid insert: 39,005 bp.
[0063] SEQ ID NO:7 is the pDAB2097 cosmid ORF1: nucleotides 1-1,533 of SEQ ID NO:6.
[0064] SEQ ID NO:8 is the pDAB2097 cosmid ORF1 deduced protein: 511 aa.
[0065] SEQ ID NO:9 is the pDAB2097 cosmid ORF2 (xptD1
[0066] SEQ ID NO:10 is the pDAB2097 cosmid ORF2 deduced protein: 1,391 aa.
[0067] SEQ ID NO:11 is the pDAB2097 cosmid ORF3: nucleotides 5,764-7,707 of SEQ ID NO:6.
[0068] SEQ ID NO:12 is the pDAB2097 cosmid ORF3 deduced protein: 648 aa.
[0069] SEQ ID NO:13 is the pDAB2097 cosmid ORF4 (xptA1
[0070] SEQ ID NO:14 is the pDAB2097 cosmid ORF4 deduced protein: 2,523 aa.
[0071] SEQ ID NO:15 is the pDAB2097 cosmid ORF5 (xptB1
[0072] SEQ ID NO:16 is the pDAB2097 cosmid ORF5 deduced protein: 1,016 aa.
[0073] SEQ ID NO:17 is the pDAB2097 cosmid ORF6 (xptC1
[0074] SEQ ID NO:18 is the pDAB2097 cosmid ORF6 deduced protein: 1,493 aa.
[0075] SEQ ID NO:19 is the pDAB2097 cosmid ORF7 (xptA2
[0076] SEQ ID NO:20 is the pDAB2097 cosmid ORF7 deduced protein: 2,538 aa.
[0077] SEQ ID NO:21 is the TcdA gene and protein sequence from GENBANK Accession No. AF188483.
[0078] SEQ ID NO:22 is the TcdB1 gene and protein sequence from GENBANK Accession No. AF346500.
[0079] SEQ ID NO:23 is the forward primer used to amplify the TcdB1 sequence from plasmid pBC-AS4.
[0080] SEQ ID NO:24 is the reverse primer used to amplify the TcdB1 sequence from plasmid pBC-AS4.
[0081] SEQ ID NO:25 is the gene and protein sequence for TccC1 from GENBANK Accession No. AAC38630.1.
[0082] SEQ ID NO:26 is the forward primer used to amplify TccC1 from the pBC KS+ vector.
[0083] SEQ ID NO:27 is the reverse primer used to amplify TccC1 from the pBC KS+ vector.
[0084] SEQ ID NO:28 is the forward primer used to amplify xptA2
[0085] SEQ ID NO:29 is the reverse primer used to amplify xptA2
[0086] SEQ ID NO:30 is the forward primer used to amplify xptC1
[0087] SEQ ID NO:31 is the reverse primer used to amplify xptC1
[0088] SEQ ID NO:32 is the forward primer used to amplify xptB1
[0089] SEQ ID NO:33 is the reverse primer used to amplify xptB1
[0090] SEQ ID NO:34 is the amino acid sequence of the XptA2
[0091] SEQ ID NO:35 is the nucleic acid sequence of ORF3, of
[0092] SEQ ID NO:36 is the amino acid sequence encoded by
[0093] SEQ ID NO:37 is the nucleic acid sequence of ORF4, of
[0094] SEQ ID NO:38 is the amino acid sequence encoded by
[0095] SEQ ID NO:39 is the nucleic acid sequence of ORF5, of
[0096] SEQ ID NO:40 is the amino acid sequence encoded by
[0097] SEQ ID NO:41 is the nucleic acid sequence of ORF6 (short), of
[0098] SEQ ID NO:42 is a protein sequence encoded by
[0099] SEQ ID NO:43 is an alternate (long) protein sequence (PptC1
[0100] SEQ ID NO:44 is the nucleotide sequence for TcdB2.
[0101] SEQ ID NO:45 is the amino acid sequence of the TcdB2 protein.
[0102] SEQ ID NO:46 is the nucleotide sequence of TccC3.
[0103] SEQ ID NO:47 is the amino acid sequence of the TccC3 protein.
[0104] SEQ ID NO:48 is the native xptB1
[0105] SEQ ID NO:49 is the native xptB1
[0106] SEQ ID NO:50 is the native xptC1
[0107] SEQ ID NO:51 is the native XptC1
[0108] SEQ ID NO:52 is the Xba I to Xho I fragment of expression plasmid pDAB6031 comprising the native xptB1
[0109] SEQ ID NO:53 is the Xba I to Xho I fragment of expression plasmid pDAB6032 comprising the native xptC1
[0110] SEQ ID NO:54 is the Xba I to Xho I fragment of expression plasmid pDAB6033 comprising the native xptB1
[0111] SEQ ID NO:55 is the nucleic acid sequence of ORF6 (long; pptC1
[0112] SEQ ID NO:56 is the gene and protein sequence for TcaC from GENBANK Accession No. AF346497.1.
[0113] SEQ ID NO:57 is the gene and protein sequence for TccC5 from GENBANK Accession No. AF346500.2.
[0114] SEQ ID NO:58 is the protein sequence for TccC2 from GENBANK Accession No. AAL18492.
[0115] SEQ ID NO:59 shows the amino acid sequence for the TcbA
[0116] SEQ ID NO:60 shows the amino acid sequence for the SepB protein.
[0117] SEQ ID NO:61 shows the amino acid sequence for the SepC protein.
[0118] SEQ ID NO:62 shows the amino acid sequence for the TcdA2
[0119] SEQ ID NO:63 shows the amino acid sequence for the TcdA4
[0120] SEQ ID NO:64 shows the amino acid sequence for the TccC4
[0121] The subject invention relates to the novel use of toxin complex (TC) proteins, obtainable from organisms such as
[0122] It was known that some TC proteins have “stand alone” insecticidal activity, and other TC proteins were known to enhance the activity of the stand-alone toxins produced by the same given organism. In particularly preferred embodiments of the subject invention, the toxicity of a “stand-alone” TC protein (from
[0123] There are three main types of TC proteins. As referred to herein, Class A proteins (“Protein A”) are stand alone toxins. Native Class A proteins are approximately 280 kDa.
[0124] Class B proteins (“Protein B”) and Class C proteins (“Protein C”) enhance the toxicity of Class A proteins. As used referred to herein, native Class B proteins are approximately 170 kDa, and native Class C proteins are approximately 112 kDa.
[0125] Examples of Class A proteins are TcbA, TcdA, XptA1, and XptA2. Examples of Class B proteins are TcaC, TcdB, XptB1
[0126] The exact mechanism of action for the toxicity and enhancement activities are not currently known, but the exact mechanism of action is not important. What is important is that the target insect eats or otherwise ingests the A, B, and C proteins.
[0127] It was known that the TcdA protein is active, alone, against
[0128] Although the complex of (TcbA or TcdA)+(TcaC+TccC) might appear to be a similar arrangement as the complex of (XptA1 or XptA2)+(XptC2+XptB1), each
[0129] It is in this context that it was discovered, as described herein, that
[0130] The subject invention can be performed in many different ways. A plant can be engineered to produce two types of Class A proteins and a single pair of potentiators (B and C proteins). Every cell of the plant, or every cell in a given type of tissue (such as roots or leaves) can have genes to encode the two A proteins and the B and C pair.
[0131] Alternatively, different cells of the plant can produce only one (or more) of each of these proteins. In this situation, when an insect bites and eats tissues of the plant, it could eat a cell that produces the first Protein A, another cell that produces the second Protein A, another cell that produces the B protein, and yet another cell that produces the C protein. Thus, what would be important is that the plant (not necessarily each plant cell) produces two A proteins, the B protein, and the C protein of the subject invention so that insect pests eat all four of these proteins when they eat tissue of the plant.
[0132] Aside from transgenic plants, there are many other ways of administering the proteins, in a combination of the subject invention, to the target pest. Spray-on applications are known in the art. Some or all of the A, B, and C proteins can be sprayed (the plant could produce one or more of the proteins and the others could be sprayed). Various types of bait granules for soil applications, for example, are also known in the art and can be used according to the subject invention.
[0133] Many combinations of various TC proteins are shown herein to function in surprising, new ways. One example set forth herein shows the use of TcdB1 and TccC1 to enhance the activity of XptA2 against corn earworm, for example. Another example set forth herein is the use of XptB1 together with TcdB1 to enhance the activity of TcdA against corn rootworm, for example. Similarly, and also surprisingly, it was further discovered that TC proteins from Protein A Protein B Protein C (Toxin) (Potentiator 1) (Potentiator 2) XptA2 (TcaC-like) XptA2 XptB1
[0134] The use of these and other combinations will now be apparent to those skilled in the art having the benefit of the subject disclosure.
[0135] Stand-alone toxins such as TcbA, TcdA, XptA1, and XptA2 are each in the approximate size range of 280 kDa. TcaC, TcdB1, TcdB2, and XptC1 are each approximately 170 kDa. TccC1, TccC3, and XptB1are each approximately 112 kDa. Thus, preferred embodiments of the subject invention include the use of a 280-kDa type TC protein toxin (as described herein) with a 170-kDa class TC protein (as described herein) together with a 112-kDa class TC protein (as described herein), wherein at least one of said three proteins is derived from a source organism (such as
[0136] The subject invention provides one skilled in the art with many surprising advantages. Among the most important advantages is that one skilled in the art will now be able to use a single pair of potentiators to enhance the activity of a stand-alone
[0137] Thus, the subject invention includes a transgenic plant and/or a transgenic plant cell that co-expresses a polynucleotide or polynucleotides encoding two (or more) different stand-alone TC protein toxins, and a polynucleotide or polynucleotides encoding a single pair of TC protein potentiators—a Class B protein and a Class C protein—wherein one or both of said potentiators is/are derived from a bacterium of a genus that is different from the genus from which one of the stand-alone TC protein toxins is derived. Accordingly, one can now obtain a cell having two (or more) TC protein toxins (Class A proteins) that are enhanced by a single pair of protein potentiators (a Class B and a Class C protein). There was no previous suggestion to produce such cells, and certainly no expectation that both (or all) such toxins produced by said cell would be active to adequate levels (due to the surprising enhancement as reported herein). TC proteins, as the term is used herein, are known in the art. Such proteins include stand-alone toxins and potentiators. Bacteria known to produce TC proteins include those of the following genera:
[0138] Examples of stand-alone (Class A) toxins, as the term is used herein, include TcbA and TcdA from
[0139] There are two main types or classes of potentiators, as the term is used herein. Examples of the “Class B” of potentiators (sometimes referred to herein as Potentiator 1) include TcaC, TcdB1, and TcdB2 from
[0140] Examples of the “Class C” potentiators (sometimes referred to herein as Potentiator 2) include TccC1 and TccC3 from
[0141] WO 02/94867, U.S. patent application 20020078478, and Waterfield et al. (
[0142] Thus, one embodiment of the subject invention includes a transgenic plant or plant cell that produces one, two, or more types of stand-alone TC protein toxins, and a single pair of potentiators: Potentiator 1 and Potentiator 2 (examples of each of these three components are given above and elsewhere herein) wherein at least one of said TC proteins is derived from an organism of a genus that is different from the genes from which one or more of the other TC proteins is derived.
[0143] It should be clear that examples of the subject invention include a transgenic plant or plant cell that produces/co-expresses one type of a
[0144] It should also be clear that the subject invention can be defined in many ways—other than in terms of what is co-expressed by a transgenic plant or plant cell. For example, the subject invention includes methods of potentiating the activity of one or more stand-alone TC protein toxin(s) by coexpressing/coproducing it (or them) with a single pair of potentiators, wherein one or both of the potentiators is/are derived from an organism of a genus that is different from the genus of the organism from which the TC protein toxin is derived. The subject invention also includes methods of controlling insect (and like) pests by feeding them one or more types of TC protein toxins together with one or more pairs of potentiators (e.g., TcbA and XptA1 and XptC1 and XptB1, possibly without TcaC and TccC), including cells that produced this combination of proteins, wherein one or both of the potentiators is/are derived from an organism of a genus that differs from one or both of the stand-alone toxins.
[0145] Such arrangements were not heretofore contemplated or expected to have activity. One way of understanding why the subject results were surprising is to consider the sequence relatedness of some of the protein components exemplified herein. For example, XptA2, a stand-alone toxin from
[0146] TcaC (a
[0147] Some examples of components for use according to the subject invention, and their relatedness to each other, include:
Class A Proteins Sequence identity to W-14 TcdA Name Reference (GenBank Accession NO. AAF05542.1) SEQ ID NO: 13 of U.S. ˜93% Pat. No. 6,281,413B1 Encoded by bases 2416 to 9909 of ˜57% SEQ ID NO: 11 of U.S. Pat. No. 6,281,413B1 Sequence identity to W-14 TcdA Name Reference (GenBank Accession NO. AAF05542.1) GenBank Accession No. (˜50% sequence identity to AAC38627.1 (reproduced here W-14 TcdA) as SEQ ID NO: 59) Sequence identity to Xwi XptA1 Name Reference (disclosed herein as SEQ ED NO: 14) GenBank Accession No. ˜96% CAC38401.1 (AJ308438) Sequence identity to Xwi XptA2 Name Reference (disclosed herein as SEQ ID NO:20) GenBank Accession No. ˜95% CAC38404.1 (AJ308438)
[0148]
Class B Proteins Sequence identity to Name Identifier (GenBank Accession No. AAL18487.1) SEQ ID NO: 14 of U.S. ˜93% Pat. No. 6,281,413B1 Encoded by bases 9966 to 14633 ˜71% of SEQ ID NO: 11 Of U.S. Pat. No. 6,281,413B1 GenBank Accession No. ˜58% AF046867 Sequence identity to Xwi XptC1 Name Identifier (disclosed herein as SEQ ID NO: 18) GenBank Accession No. ˜90% CAC38403.1
[0149]
Class C Proteins Sequence identity to Name Identifier (GenBank Accession No. AAC38630.1) SEQ ID NO: 12 of U.S. ˜51% Pat. No. 6,281,413B1 GenBank Accession No. ˜48% AAL18492 SEQ ID NO: 45 ˜53% Sequence identity to Xwi XptB1 Name Identifier (disclosed herein as SEQ ID NO: 16) GenBank Accession No. ˜96% CAC38402 Encoded by bases 2071 to 4929 ˜48% 2071 of
[0150] Thus, referring to the genus of a bacterium from which a TC protein was derived is not simply a matter of arbitrary nomenclature. As illustrated above, doing so helps define a class of TC proteins that are relatively conserved amongst themselves (such as a given type of TC protein produced by
[0151] Another way to define each TC protein component of the subject invention is by a given protein's degree of sequence identity to a given toxin or potentiator. Means for calculating identity scores are provided herein. Thus, one specific embodiment of the subject invention includes a transgenic plant or plant cell co-producing a toxin having at least 75% sequence identity with XptA2, a toxin having at least 75% identity with TcdA or TcbA, a potentiator having at least 75% sequence identity with TcdB1 or TcdB2, and a potentiator having at least 75% sequence identity with TccC1 or TccC3. Other TC proteins can be substituted into the above formula, in accordance with the teachings of the subject invention. Other, more specific ranges of identity scores are provided elsewhere herein.
[0152] Yet another way of defining a given type of TC protein component of the subject invention is by the hybridization characteristics of the polynucleotide that encodes it. Much more detailed information regarding such “tests” and hybridization (and wash) conditions is provided throughout the subject specification. Thus, TC proteins for use according to the subject invention can be defined by the ability of a polynucleotide that encodes the TC protein to hybridize with a given “tc” gene.
[0153] Applying that guidance to a particular example, an XptA2-type toxin of the subject invention could be defined as being encoded by a polynucleotide, wherein a nucleic acid sequence that codes for said ZptA2-type toxin hybridizes with the xptA2 gene of SEQ ID NO:19, wherein hybridization is maintained after hybridization and wash under any such conditions described or suggested herein (such as the examples of low, moderate, and high stringency hybridization/wash conditions mentioned herein). Any of the other exemplified or suggested TC proteins (including potentiators or other toxins) could be substituted for XptA2 in this definition, such as TcdB2, TccC3, TcdA, and TcbA.
[0154] Thus, the subject invention includes a transgenic plant, a transgenic plant cell, or a bacterial cell that co-expresses certain combinations of polynucleotides that encode TC proteins of the subject invention. It should be clear that the subject invention includes a transgenic plant or plant cell that co-expresses two toxin genes and only one pair of potentiators. Thus, the subject invention includes a trangenic plant or plant cell comprising one or more polynucleotides encoding a toxin in a class of a toxin indicated below as Toxin Pair 1, 2, 3, or 4 as follows, and wherein said plant or cell consists of DNA encoding one pair of potentiators selected from the group consisting of proteins in the class of potentiators shown in Potentiator Pair 1, 2, 3, 4, 5, or 6, as indicated below. Stated another way, said plant or cell consists of a polynucleotide segment encoding one potentiator of Potentiator Pair 1, 2, 3, 4, 5, or 6, and said plant or cell consists of another polynucleotide segment encoding the other potentiator of the selected Potentiator Pair.
Toxin Pair # 1 TcbA & XptA1 2 TcbA & XptA2 3 TcdA & XptA1 4 TcdA & XptA2 Potentiator Pair # 1 TcdB1 & TccC 2 TcaC & TccC 3 XptC1 & TccC 4 TcdB1 & XptB1 5 TcaC & XptB1 6 XptC1 & XptB1
[0155] The plant or cell can comprise genes encoding additional TC protein toxins (e.g., so that the cell produces TcbA as well as TcdA, and/or XptA1 and XptA2), but only one pair of potentiators is used according to preferred embodiments of the subject invention. (Of course, the cell or plant will produce multiple copies of the potentiators; the key is that additional transformation events can be avoided.)
[0156] Further embodiments of the subject invention include a transgenic cell or plant that co-expresses a stand-alone protein toxin and a single (no more than one) potentiator pair comprising at least one “heterologous” (derived from a bacterium of a genus that is other than the genus of the organism from which the toxin is derived) TC protein. The subject invention also includes potentiating the insecticidal activity of a TC protein toxin with a pair of TC proteins that are potentiators, wherein at least one (one or both) of said TC protein potentiators is a heterologous TC protein, with respect to the TC protein toxin it helps to potentiate. Sets of toxins and the potentiators used to enhance the toxin include the following combinations:
TcbA XptC1 XptB1 TcbA TcdB1 XptB1 TcbA TcaC XptB1 TcbA XptC1 TccC1 TcdA XptC1 XptB1 TcdA TcdB1 XptB1 TcdA TcaC XptB1 TcdA XptC1 TccC1 XptA1 TcdB1 TccC1 XptA1 TcdB1 XptB1 XptA1 TcaC TccC1 XptA1 TcaC XptB1 XptA1 XptC1 TccC1 XptA2 TcdB1 TccC1 XptA2 TcdB1 XptB1 XptA2 TcaC TccC1 XptA2 TcaC XptB1 XptA2 XptC1 TccC1
[0157] It should be clear that the above matrices are intended to include, for example, TcdB2+TccC3 (a preferred pair of potentiators) with any of the toxins such as XptA1 and/or XptA2 (together with TcbA and/or TcdA).
[0158] Other embodiments and combinations will be apparent to one skilled in the art having the benefit of this disclosure.
[0159] The subject invention also provides “mixed pairs” of potentiators such as Potentiator Pairs 3, 4, and 5 as illustrated above. Such combinations were not heretofore expected (or suggested) to be active as TC protein toxin enhancers. Thus, such “heterologous” combinations of potentiators can now be selected to maximize their ability to enhance two (for example) insecticidal toxins. That is, one might now find that, for a given use, TcdB1 and XptB1 is a more desirable pair of potentiators than is XptC1 and XptB1, for example. Again, this is surprising given the relative degree of sequence divergence between a given
[0160] The subject invention is not limited to 280 kDa TC protein toxins and a heterologous 112 kDa and/or 170·kDa TC protein potentiator. As this is the first observation of the ability to “mix and match”
[0161] The subject invention also includes the use of a transgenic plant producing a subject TC protein combination together with one or more
[0162] Proteins and toxins. The present invention provides easily administered, functional proteins. The present invention also provides a method for delivering insecticidal toxins that are functionally active and effective against many orders of insects, preferably lepidopteran insects. By “functional activity” (or “active against”) it is meant herein that the protein toxins function as orally active insect control agents (alone or in combination with other proteins), that the proteins have a toxic effect (alone or in combination with other proteins), or are able to disrupt or deter insect growth and/or feeding which may or may not cause death of the insect. When an insect comes into contact with an effective amount of a “toxin” of the subject invention delivered via transgenic plant expression, formulated protein composition(s), sprayable protein composition(s), a bait matrix or other delivery system, the results are typically death of the insect, inhibition of the growth and/or proliferation of the insect, and/or prevention of the insects from feeding upon the source (preferably a transgenic plant) that makes the toxins available to the insects. Functional proteins of the subject invention can also work together or alone to enhance or improve the activity of one or more other toxin proteins. The terms “toxic,” “toxicity,” or “toxin” as used herein are meant to convey that the subject “toxins” have “functional activity” as defined herein.
[0163] Complete lethality to feeding insects is preferred, but is not required to achieve functional activity. If an insect avoids the toxin or ceases feeding, that avoidance will be useful in some applications, even if the effects are sublethal or lethality is delayed or indirect. For example, if insect resistant transgenic plants are desired, the reluctance of insects to feed on the plants is as useful as lethal toxicity to the insects because the ultimate objective is avoiding insect-induced plant damage.
[0164] There are many other ways in which toxins can be incorporated into an insect's diet. For example, it is possible to adulterate the larval food source with the toxic protein by spraying the food with a protein solution, as disclosed herein. Alternatively, the purified protein could be genetically engineered into an otherwise harmless bacterium, which could then be grown in culture, and either applied to the food source or allowed to reside in the soil in an area in which insect eradication was desirable. Also, the protein could be genetically engineered directly into an insect food source. For instance, the major food source for many insect larvae is plant material. Therefore the genes encoding toxins can be transferred to plant material so that said plant material expresses the toxin of interest.
[0165] Transfer of the functional activity to plant or bacterial systems typically requires nucleic acid sequences, encoding the amino acid sequences for the toxins, integrated into a protein expression vector appropriate to the host in which the vector will reside. One way to obtain a nucleic acid sequence encoding a protein with functional activity is to isolate the native genetic material from the bacterial species which produce the toxins, using information deduced from the toxin's amino acid sequence, as disclosed herein. The native sequences can be optimized for expression in plants, for example, as discussed in more detail below. Optimized polynucleotide can also be designed based on the protein sequence.
[0166] The subject invention provides classes of TC proteins having toxin activities. One way to characterize these classes of toxins and the polynucleotides that encode them is by defining a polynucleotide by its ability to hybridize, under a range of specified conditions, with an exemplified nucleotide sequence (the complement thereof and/or a probe or probes derived from either strand) and/or by their ability to be amplified by PCR using primers derived from the exemplified sequences.
[0167] There are a number of methods for obtaining the pesticidal toxins for use according to the subject invention. For example, antibodies to the pesticidal toxins disclosed herein can be used to identify and isolate other toxins from a mixture of proteins. Specifically, antibodies maybe raised to the portions of the toxins which are most constant and most distinct from other toxins. These antibodies can then be used to specifically identify equivalent toxins with the characteristic activity by immunoprecipitation, enzyme linked immunosorbent assay (ELISA), or immuno-blotting. Antibodies to the toxins disclosed herein, or to equivalent toxins, or to fragments of these toxins, can be readily prepared using standard procedures. Such antibodies are an aspect of the subject invention. Toxins of the subject invention can be obtained from a variety of sources/source microorganisms.
[0168] One skilled in the art would readily recognize that toxins (and genes) of the subject invention can be obtained from a variety of sources. A toxin “from” or “obtainable from” any of the subject isolates referred to or suggested herein means that the toxin (or a similar toxin) can be obtained from the isolate or some other source, such as another bacterial strain or a plant. “Derived from” also has this connotation, and includes proteins obtainable from a given type of bacterium that are modified for expression in a plant, for example. One skilled in the art will readily recognize that, given the disclosure of a bacterial gene and toxin, a plant can be engineered to produce the toxin. Antibody preparations, nucleic acid probes (DNA and RNA), and the like may be prepared using the polynucleotide and/or amino acid sequences disclosed herein and used to screen and recover other toxin genes from other (natural) sources.
[0169] Polynucleotides and probes. The subject invention further provides nucleotide sequences that encode the TC proteins for use according to the subject invention. The subject invention further provides methods of identifying and characterizing genes that encode proteins having toxin activity. In one embodiment, the subject invention provides unique nucleotide sequences that are useful as hybridization probes and/or primers for PCR techniques. The primers produce characteristic gene fragments that can be used in the identification, characterization, and/or isolation of specific toxin genes. The nucleotide sequences of the subject invention encode toxins that are distinct from previously described toxins.
[0170] The polynucleotides of the subject invention can be used to form complete “genes” to encode proteins or peptides in a desired host cell. For example, as the skilled artisan would readily recognize, the subject polynucleotides can be appropriately placed under the control of a promoter in a host of interest, as is readily known in the art.
[0171] As the skilled artisan knows, DNA typically exists in a double-stranded form. In this arrangement, one strand is complementary to the other strand and vice versa. As DNA is replicated in a plant (for example), additional complementary strands of DNA are produced. The “coding strand” is often used in the art to refer to the strand that binds with the anti-sense strand. The mRNA is transcribed from the “anti-sense” strand of DNA. The “sense” or “coding” strand has a series of codons (a codon is three nucleotides that can be read as a three-residue unit to specify a particular amino acid) that can be read as an open reading frame (ORF) to form a protein or peptide of interest. In order to produce a protein in vivo, a strand of DNA is typically transcribed into a complementary strand of mRNA which is used as the template for the protein. Thus, the subject invention includes the use of the exemplified polynucleotides shown in the attached sequence listing and/or equivalents including the complementary strands. RNA and PNA (peptide nucleic acids) that are functionally equivalent to the exemplified DNA are included in the subject invention.
[0172] In one embodiment of the subject invention, bacterial isolates can be cultivated under conditions resulting in high multiplication of the microbe. After treating the microbe to provide single-stranded genomic nucleic acid, the DNA can be contacted with the primers of the invention and subjected to PCR amplification. Characteristic fragments of toxin-encoding genes will be amplified by the procedure, thus identifying the presence of the toxin-encoding gene(s).
[0173] Further aspects of the subject invention include genes and isolates identified using the methods and nucleotide sequences disclosed herein. The genes thus identified encode toxins active against pests.
[0174] Proteins and genes for use according to the subject invention can be identified and obtained by using oligonucleotide probes, for example. These probes are detectable nucleotide sequences which may be detectable by virtue of an appropriate label or may be made inherently fluorescent as described in International Application No. WO 93/16094. The probes (and the polynucleotides of the subject invention) may be DNA, RNA, or PNA. In addition to adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U; for RNA molecules), synthetic probes (and polynucleotides) of the subject invention can also have inosine (a neutral base capable of pairing with all four bases; sometimes used in place of a mixture of all four bases in synthetic probes). Thus, where a synthetic, degenerate oligonucleotide is referred to herein, and “N” or “n” is used generically, “N” or “n” can be G, A, T, C, or inosine. Ambiguity codes as used herein are in accordance with standard IUPAC naming conventions as of the filing of the subject application (for example, R means A or G, Y means C or T, etc.).
[0175] As is well known in the art, if a probe molecule hybridizes with a nucleic acid sample, it can be reasonably assumed that the probe and sample have substantial homology/similarity/identity. Preferably, hybridization of the polynucleotide is first conducted followed by washes under conditions of low, moderate, or high stringency by techniques well-known in the art, as described in, for example, Keller, G. H., M. M. Manak (1987)
[0176] Detection of the probe provides a means for determining in a known manner whether hybridization has been maintained. Such a probe analysis provides a rapid method for identifying toxin-encoding genes of the subject invention. The nucleotide segments which are used as probes according to the invention can be synthesized using a DNA synthesizer and standard procedures. These nucleotide sequences can also be used as PCR primers to amplify genes of the subject invention.
[0177] Hybridization characteristics of a molecule can be used to define polynucleotides of the subject invention. Thus the subject invention includes polynucleotides (and/or their complements, preferably their full complements) that hybridize with a polynucleotide exemplified herein. That is, one way to define a tcdA-like gene (and the protein it encodes), for example, is by its ability to hybridize (under any of the conditions specifically disclosed herein) with a previously known, including a specifically exemplified, tcdA gene. The same is true for xptA2-, tcaC-, tcaA-, tcaB-, tcdB-, tccC-, and xptB1-like genes and related proteins, for example. This also includes the tcdB2 and tccC3 genes.
[0178] As used herein, “stringent” conditions for hybridization refers to conditions which achieve the same, or about the same, degree of specificity of hybridization as the conditions employed by the current applicants. Specifically, hybridization of immobilized DNA on Southern blots with
[0179] Washes are typically carried out as follows:
[0180] (1) Twice at room temperature for 15 minutes in 1×SSPE, 0.1% SDS (low stringency wash).
[0181] (2) Once at Tm-20° C. for 15 minutes in 0.2×SSPE, 0.1% SDS (moderate stringency wash).
[0182] For oligonucleotide probes, hybridization was carried out overnight at 10-20° C. below the melting temperature (Tm) of the hybrid in 6×SSPE, 5×Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. Tm for oligonucleotide probes was determined by the following formula:
[0183] (Suggs, S. V., T. Miyake, E. H. Kawashime, M. J. Johnson, K. Itakura, and R. B. Wallace [1981
[0184] Washes were typically carried out as follows:
[0185] (1) Twice at room temperature for 15 minutes 1×SSPE, 0.1% SDS (low stringency wash).
[0186] (2) Once at the hybridization temperature for 15 minutes in 1×SSPE, 0.1% SDS (moderate stringency wash).
[0187] In general, salt and/or temperature can be altered to change stringency. With a labeled DNA fragment >70 or so bases in length, the following conditions can be used:
Low: 1 or 2 × SSPE, room temperature Low: 1 or 2 × SSPE, 42° C. Moderate: 0.2 × or 1 × SSPE, 65° C. High: 0.1 × SSPE, 65° C.
[0188] Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid, and, as noted above, a certain degree of mismatch can be tolerated. Therefore, the probe sequences of the subject invention include mutations (both single and multiple), deletions, insertions of the described sequences, and combinations thereof, wherein said mutations, insertions and deletions permit formation of stable hybrids with the target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence in many ways, and these methods are known to an ordinarily skilled artisan. Other methods may become known in the future.
[0189] PCR technology. Polymerase Chain Reaction (PCR) is a repetitive, enzymatic, primed synthesis of a nucleic acid sequence. This procedure is well known and commonly used by those skilled in this art (see Mullis, U.S. Pat. Nos. 4,683,195,4,683,202, and 4,800,159; Saiki, Randall K., Stephen Scharf, Fred Faloona, Kary B. Mullis, Glenn T. Horn, Henry A. Erlich, Norman Arnheim [1985] “Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia,”
[0190] The DNA sequences of the subject invention can be used as primers for PCR amplification. In performing PCR amplification, a certain degree of mismatch can be tolerated between primer and template. Therefore, mutations, deletions, and insertions (especially additions of nucleotides to the 5′ end) of the exemplified primers fall within the scope of the subject invention. Mutations, insertions, and deletions can be produced in a given primer by methods known to an ordinarily skilled artisan.
[0191] Modification of genes and toxins. The genes and toxins useful according to the subject invention include not only the specifically exemplified full-length sequences, but also portions, segments and/or fragments (including internal and/or terminal deletions compared to the full-length molecules) of these sequences, variants, mutants, chimerics, and fusions thereof. Proteins of the subject invention can have substituted amino acids so long as they retain the characteristic pesticidal/functional activity of the proteins specifically exemplified herein. “Variant” genes have nucleotide sequences that encode the same toxins or equivalent toxins having pesticidal activity equivalent to an exemplified protein. The terms “variant proteins” and “equivalent toxins” refer to toxins having the same or essentially the same biological/functional activity against the target pests and equivalent sequences as the exemplified toxins. As used herein, reference to an “equivalent” sequence refers to sequences having amino acid substitutions, deletions, additions, or insertions which improve or do not adversely affect pesticidal activity. Fragments retaining pesticidal activity are also included in this definition. Fragments and other equivalents that retain the same or similar function, or “toxin activity,” as a corresponding fragment of an exemplified toxin are within the scope of the subject invention. Changes, such as amino acid substitutions or additions, can be made for a variety of purposes, such as increasing (or decreasing) protease stability of the protein (without materially/substantially decreasing the functional activity of the toxin).
[0192] Equivalent toxins and/or genes encoding these equivalent toxins can be obtained/derived from wild-type or recombinant bacteria and/or from other wild-type or recombinant organisms using the teachings provided herein. Other
[0193] Variations of genes may be readily constructed using standard techniques for making point mutations, for example. In addition, U.S. Pat. No. 5,605,793, for example, describes methods for generating additional molecular diversity by using DNA reassembly after random fragmentation. Variant genes can be used to produce variant proteins; recombinant hosts can be used to produce the variant proteins. Using these “gene shuffling” techniques, equivalent genes and proteins can be constructed that comprise any 5, 10, or 20 contiguous residues (amino acid or nucleotide) of any sequence exemplified herein. As one skilled in the art knows, the gene shuffling techniques can be adjusted to obtain equivalents having, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, or 500 contiguous residues (amino acid or nucleotide), corresponding to a segment (of the same size) in any of the exemplified or suggested sequences (or the complements (full complements) thereof). Similarly sized segments, especially those for conserved regions, can also be used as probes and/or primers.
[0194] Fragments of full-length genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as Bal31 or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which encode active fragments may be obtained using a variety of restriction enzymes. Proteases may be used to directly obtain active fragments of these toxins.
[0195] It is within the scope of the invention as disclosed herein that toxins (and TC proteins) may be truncated and still retain functional activity. By “truncated toxin” is meant that a portion of a toxin protein may be cleaved and yet still exhibit activity after cleavage. Cleavage can be achieved by proteases inside or outside of the insect gut. Furthermore, effectively cleaved proteins can be produced using molecular biology techniques wherein the DNA bases encoding said toxin are removed either through digestion with restriction endonucleases or other techniques available to the skilled artisan. After truncation, said proteins can be expressed in heterologous systems such as
[0196] In some cases, especially for expression in plants, it can be advantageous to use truncated genes that express truncated proteins. Höfte et al. 1989, for example, discussed in the Background Section above, discussed protoxin and core toxin segments of B.t. toxins. Preferred truncated genes will typically encode 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% of the full-length protein. The Background section also discusses protease processing and reassembly of the segments of TcdA and TcbA, for example.
[0197] Certain toxins/TC proteins of the subject invention have been specifically exemplified herein. As these toxins/TC proteins are merely exemplary of the proteins of the subject invention, it should be readily apparent that the subject invention comprises variant or equivalent proteins (and nucleotide sequences coding for equivalents thereof) having the same or similar toxin activity of the exemplified proteins. Equivalent proteins will have amino acid similarity (and/or homology) with an exemplified toxin/TC protein. The amino acid identity will typically be greater than 60%, preferably greater than 75%, more preferably greater than 80%, even more preferably greater than 90%, and can be greater than 95%. Preferred polynucleotides and proteins of the subject invention can also be defined in terms of more particular identity and/or similarity ranges. For example, the identity and/or similarity can be 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% as compared to a sequence exemplified or suggested herein. Any number listed above can be used to define the upper and lower limits. For example, a Class A protein can be defined as having 50-90% identity with a given TcdA protein. Thus, a TcdA-like protein (and/or a tcdA-like gene) can be defined by any numerical identity score provided or suggested herein, as compared to any previously known TcdA protein, including any TcdA protein (and likewise with XptA2 proteins) specifically exemplified herein. The same is true for any other protein or gene, to be used according to the subject invention, such as TcaC-, TcaA-, TcaB-, TcdB-, TccC-, and XptB2-like proteins and genes. Thus, this applies to potentiators (such as TcdB2 and TccC3) and stand-alone toxins.
[0198] Unless otherwise specified, as used herein, percent sequence identity and/or similarity of two nucleic acids is determined using the algorithm of Karlin and Altschul (1990),
[0199] The amino acid homology/similarity/identity will be highest in critical regions of the protein that account for its toxin activity or that are involved in the determination of three-dimensional configurations that are ultimately responsible for the toxin activity. In this regard, certain amino acid substitutions are acceptable and can be expected to be tolerated. For example, these substitutions can be in regions of the protein that are not critical to activity. Analyzing the crystal structure of a protein, and software-based protein structure modeling, can be used to identify regions of a protein that can be modified (using site-directed mutagenesis, shuffling, etc.) to actually change the properties and/or increase the functionality of the protein.
[0200] Various properties and three-dimensional features of the protein can also be changed without adversely affecting the toxin activity/functionality of the protein. Conservative amino acid substitutions can be expected to be tolerated/to not adversely affect the three-dimensional configuration of the molecule. Amino acids can be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution is not adverse to the biological activity of the compound. Table 1 provides a listing of examples of amino acids belonging to each class.
TABLE 1 Class of Amino Acid Examples of Amino Acids Nonpolar Ala, Val, Leu, Ile, Pro, Met, Phe, Trp Uncharged Polar Gly, Ser, Thr, Cys, Tyr, Asn, Gln Acidic Asp, Glu Basic Lys, Arg, His
[0201] In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the functional/biological/toxin activity of the protein.
[0202] As used herein, reference to “isolated” polynucleotides and/or “purified” toxins refers to these molecules when they are not associated with the other molecules with which they would be found in nature. Thus, reference to “isolated” and/or “purified” signifies the involvement of the “hand of man” as described herein. For example, a bacterial toxin “gene” of the subject invention put into a plant for expression is an “isolated polynucleotide.” Likewise, a
[0203] Because of the degeneracy/redundancy of the genetic code, a variety of different DNA sequences can encode the amino acid sequences disclosed herein. It is well within the skill of a person trained in the art to create alternative DNA sequences that encode the same, or essentially the same, toxins. These variant DNA sequences are within the scope of the subject invention.
[0204] Optimization of sequence for expression in plants. To obtain high expression of heterologous genes in plants it may be preferred to reengineer said genes so that they are more efficiently expressed in (the cytoplasm of) plant cells. Maize is one such plant where it may be preferred to re-design the heterologous gene(s) prior to transformation to increase the expression level thereof in said plant. Therefore, an additional step in the design of genes encoding a bacterial toxin is reengineering of a heterologous gene for optimal expression.
[0205] One reason for the reengineering of a bacterial toxin for expression in maize is due to the non-optimal G+C content of the native gene. For example, the very low G+C content of many native bacterial gene(s) (and consequent skewing towards high A+T content) results in the generation of sequences mimicking or duplicating plant gene control sequences that are known to be highly A+T rich. The presence of some A+T-rich sequences within the DNA of gene(s) introduced into plants (e.g., TATA box regions normally found in gene promoters) may result in aberrant transcription of the gene(s). On the other hand, the presence of other regulatory sequences residing in the transcribed mRNA (e.g., polyadenylation signal sequences (AAUAAA), or sequences complementary to small nuclear RNAs involved in pre-mRNA splicing) may lead to RNA instability. Therefore, one goal in the design of genes encoding a bacterial toxin for maize expression, more preferably referred to as plant optimized gene(s), is to generate a DNA sequence having a higher G+C content, and preferably one close to that of maize genes coding for metabolic enzymes. Another goal in the design of the plant optimized gene(s) encoding a bacterial toxin is to generate a DNA sequence in which the sequence modifications do not hinder translation.
[0206] The table below (Table 2) illustrates how high the G+C content is in maize. For the data in Table 2, coding regions of the genes were extracted from GenBank (Release 71) entries, and base compositions were calculated using the MacVectorm program (Accelerys, San Diego, Calif.). Intron sequences were ignored in the calculations.
[0207] Due to the plasticity afforded by the redundancy/degeneracy of the genetic code (i.e., some amino acids are specified by more than one codon), evolution of the genomes in different organisms or classes of organisms has resulted in differential usage of redundant codons. This “codon bias” is reflected in the mean base composition of protein coding regions. For example, organisms with relatively low G+C contents utilize codons having A or T in the third position of redundant codons, whereas those having higher G+C contents utilize codons having G or C in the third position. It is thought that the presence of “minor” codons within an mRNA may reduce the absolute translation rate of that mRNA, especially when the relative abundance of the charged tRNA corresponding to the minor codon is low. An extension of this is that the diminution of translation rate by individual minor codons would be at least additive for multiple minor codons. Therefore, mRNAs having high relative contents of minor codons would have correspondingly low translation rates. This rate would be reflected by subsequent low levels of the encoded protein.
[0208] In engineering genes encoding a bacterial toxin for maize (or other plant, such as cotton or soybean) expression, the codon bias of the plant has been determined. The codon bias for maize is the statistical codon distribution that the plant uses for coding its proteins and the preferred codon usage is shown in Table 3. After determining the bias, the percent frequency of the codons in the gene(s) of interest is determined. The primary codons preferred by the plant should be determined, as well as the second, third, and fourth choices of preferred codons when multiple choices exist. A new DNA sequence can then be designed which encodes the amino sequence of the bacterial toxin, but the new DNA sequence differs from the native bacterial DNA sequence (encoding the toxin) by the substitution of the plant (first preferred, second preferred, third preferred, or fourth preferred) codons to specify the amino acid at each position within the toxin amino acid sequence. The new sequence is then analyzed for restriction enzyme sites that might have been created by the modification. The identified sites are further modified by replacing the codons with first, second, third, or fourth choice preferred codons. Other sites in the sequence which could affect transcription or translation of the gene of interest are the exon:intron junctions (5′ or 3′), poly A addition signals, or RNA polymerase termination signals. The sequence is further analyzed and modified to reduce the frequency of TA or GC doublets. In addition to the doublets, G or C sequence blocks that have more than about four residues that are the same can affect transcription of the sequence. Therefore, these blocks are also modified by replacing the codons of first or second choice, etc. with the next preferred codon of choice.
TABLE 2 Compilation of G + C contents of protein coding regions of maize genes Protein Class Range % G + C Mean % G + C Metabolic Enzymes (76) 44.4-75.3 59.0 (.+−.8.0) Structural Proteins (18) 48.6-70.5 63.6 (.+−.6.7) Regulatory Proteins (5) 57.2-68.8 62.0 (.+−.4.9) Uncharacterized Proteins (9) 41.5-70.3 64.3 (.+−.7.2) All Proteins (108) 44.4-75.3 60.8 (.+−.5.2)
[0209] It is preferred that the plant optimized gene(s) encoding a bacterial toxin contain about 63% of first choice codons, between about 22% to about 37% second choice codons, and between about 15% to about 0% third or fourth choice codons, wherein the total percentage is 100%. Most preferred the plant optimized gene(s) contains about 63% of first choice codons, at least about 22% second choice codons, about 7.5% third choice codons, and about 7.5% fourth choice codons, wherein the total percentage is 100%. The preferred codon usage for engineering genes for maize expression are shown in Table 3. The method described above enables one skilled in the art to modify gene(s) that are foreign to a particular plant so that the genes are optimally expressed in plants. The method is further illustrated in PCT application WO 97/13402.
[0210] In order to design plant optimized genes encoding a bacterial toxin, a DNA sequence is designed to encode the amino acid sequence of said protein toxin utilizing a redundant genetic code established from a codon bias table compiled for the gene sequences for the particular plant, as shown in Table 2. The resulting DNA sequence has a higher degree of codon diversity, a desirable base composition, can contain strategically placed restriction enzyme recognition sites, and lacks sequences that might interfere with transcription of the gene, or translation of the product mRNA.
TABLE 3 Preferred amino acid codons for proteins expressed in maize Amino Acid Codon* Alanine GCC/GCG Cysteine TGC/TGT Aspartic Acid GAC/GAT Glutamic Acid GAG/GAA Phenylalanine TTC/TTT Glycine GGC/GGG Histidine CAC/CAT Isoleucine ATC/ATT Lysine AAG/AAA Leucine CTG/CTC Methionine ATG Asparagine AAC/AAT Proline CCG/CCA Glutamine CAG/CAA Arginine AGG/CGC Serine AGC/TCC Threonine ACC/ACG Valine GTG/GTC Tryptophan TGG Tryrosine TAC/TAT Stop TGA/TAG
[0211] Thus, synthetic genes that are functionally equivalent to the toxins/genes of the subject invention can be used to transform hosts, including plants. Additional guidance regarding the production of synthetic genes can be found in, for example, U.S. Pat. No. 5,380,831.
[0212] Transgenic hosts. The toxin-encoding genes of the subject invention can be introduced into a wide variety of microbial or plant hosts. In preferred embodiments, transgenic plant cells and plants are used. Preferred plants (and plant cells) are corn, maize, and cotton.
[0213] In preferred embodiments, expression of the toxin gene results, directly or indirectly, in the intracellular production (and maintenance) of the pesticide proteins. Plants can be rendered insect-resistant in this manner. When transgenic/recombinant/transformed/transfected host cells (or contents thereof) are ingested by the pests, the pests will ingest the toxin. This is the preferred manner in which to cause contact of the pest with the toxin. The result is control (killing or making sick) of the pest. Sucking pests can also be controlled in a similar manner. Alternatively, suitable microbial hosts, e.g.,
[0214] Where the toxin gene is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, certain host microbes should be used. Microorganism hosts are selected which are known to occupy the “phytosphere” (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest. These microorganisms are selected so as to be capable of successfully competing in the particular environment (crop and other insect habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation.
[0215] A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera
[0216] Insertion of genes to form transgenic hosts. One aspect of the subject invention is the transformation/transfection of plants, plant cells, and other host cells with polynucleotides of the subject invention that express proteins of the subject invention. Plants transformed in this manner can be rendered resistant to attack by the target pest(s).
[0217] A wide variety of methods are available for introducing a gene encoding a pesticidal protein into the target host under conditions that allow for stable maintenance and expression of the gene. These methods are well known to those skilled in the art and are described, for example, in U.S. Pat. No. 5,135,867.
[0218] For example, a large number of cloning vectors comprising a replication system in
[0219] A large number of techniques are available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using
[0220] The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.
[0221] In some preferred embodiments of the invention, genes encoding the bacterial toxin are expressed from transcriptional units inserted into the plant genome. Preferably, said transcriptional units are recombinant vectors capable of stable integration into the plant genome and enable selection of transformed plant lines expressing mRNA encoding the proteins.
[0222] Once the inserted DNA has been integrated in the genome, it is relatively stable there (and does not come out again). It normally contains a selection marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G418, bleomycin, hygromycin, or chloramphenicol, inter alia. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA. The gene(s) of interest are preferably expressed either by constitutive or inducible promoters in the plant cell. Once expressed, the mRNA is translated into proteins, thereby incorporating amino acids of interest into protein. The genes encoding a toxin expressed in the plant cells can be under the control of a constitutive promoter, a tissue-specific promoter, or an inducible promoter.
[0223] Several techniques exist for introducing foreign recombinant vectors into plant cells, and for obtaining plants that stably maintain and express the introduced gene. Such techniques include the introduction of genetic material coated onto microparticles directly into cells (U.S. Pat. No. 4,945,050 to Cornell and U.S. Pat. No. 5,141,131 to DowElanco, now Dow AgroSciences, LLC). In addition, plants may be transformed using
[0224] As mentioned previously, the manner in which the DNA construct is introduced into the plant host is not critical to this invention. Any method which provides for efficient transformation may be employed. For example, various methods for plant cell transformation are described herein and include the use of Ti or Ri-plasmids and the like to perform
[0225] In some cases where
[0226] For transformation of plant cells using
[0227] In addition to numerous technologies for transforming plants, the type of tissue which is contacted with the foreign genes may vary as well. Such tissue would include but would not be limited to embryogenic tissue, callus tissue types I, II, and III, hypocotyl, meristem, root tissue, tissues for expression in phloem, and the like. Almost all plant tissues may be transformed during dedifferentiation using appropriate techniques described herein.
[0228] As mentioned above, a variety of selectable markers can be used, if desired. Preference for a particular marker is at the discretion of the artisan, but any of the following selectable markers may be used along with any other gene not listed herein which could function as a selectable marker. Such selectable markers include but are not limited to aminoglycoside phosphotransferase gene of transposon Tn5 (Aph II) which encodes resistance to the antibiotics kanamycin, neomycin and G418, as well as those genes which encode for resistance or tolerance to glyphosate; hygromycin; methotrexate; phosphinothricin (bialaphos); imidazolinones, sulfonylureas and triazolopyrimidine herbicides, such as chlorsulfuron; bromoxynil, dalapon and the like.
[0229] In addition to a selectable marker, it may be desirous to use a reporter gene. In some instances a reporter gene may be used with or without a selectable marker. Reporter genes are genes which are typically not present in the recipient organism or tissue and typically encode for proteins resulting in some phenotypic change or enzymatic property. Examples of such genes are provided in K. Wising et al. Ann. Rev. Genetics, 22, 421 (1988). Preferred reporter genes include the beta-glucuronidase (GUS) of the uidA locus of
[0230] In addition to plant promoter regulatory elements, promoter regulatory elements from a variety of sources can be used efficiently in plant cells to express foreign genes. For example, promoter regulatory elements of bacterial origin, such as the octopine synthase promoter, the nopaline synthase promoter, the mannopine synthase promoter; promoters of viral origin, such as the cauliflower mosaic virus (35S and 19S), 35T (which is a re-engineered 35S promoter, see U.S. Pat. No. 6,166,302, especially Example 7E) and the like may be used. Plant promoter regulatory elements include but are not limited to ribulose-1,6-bisphosphate (RUBP) carboxylase small subunit (ssu), beta-conglycinin promoter, beta-phaseolin promoter, ADH promoter, heat-shock promoters, and tissue specific promoters. Other elements such as matrix attachment regions, scaffold attachment regions, introns, enhancers, polyadenylation sequences and the like may be present and thus may improve the transcription efficiency or DNA integration. Such elements may or may not be necessary for DNA function, although they can provide better expression or functioning of the DNA by affecting transcription, mRNA stability, and the like. Such elements may be included in the DNA as desired to obtain optimal performance of the transformed DNA in the plant. Typical elements include but are not limited to Adh-intron 1, Adh-intron 6, the alfalfa mosaic virus coat protein leader sequence, the maize streak virus coat protein leader sequence, as well as others available to a skilled artisan. Constitutive promoter regulatory elements may also be used thereby directing continuous gene expression in all cells types and at all times (e.g., actin, ubiquitin, CaMV 35S, and the like). Tissue specific promoter regulatory elements are responsible for gene expression in specific cell or tissue types, such as the leaves or seeds (e.g., zein, oleosin, napin, ACP, globulin and the like) and these may also be used.
[0231] Promoter regulatory elements may also be active during a certain stage of the plant's development as well as active in plant tissues and organs. Examples of such include but are not limited to pollen-specific, embryo-specific, corn-silk-specific, cotton-fiber-specific, root-specific, seed-endosperm-specific promoter regulatory elements and the like. Under certain circumstances it may be desirable to use an inducible promoter regulatory element, which is responsible for expression of genes in response to a specific signal, such as: physical stimulus (heat shock genes), light (RUBP carboxylase), hormone (Em), metabolites, chemical, and stress. Other desirable transcription and translation elements that function in plants may be used. Numerous plant-specific gene transfer vectors are known in the art.
[0232] Standard molecular biology techniques may be used to clone and sequence the toxins described herein. Additional information may be found in Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989), Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, which is incorporated herein by reference.
[0233] Resistance Management. With increasing commercial use of insecticidal proteins in transgenic plants, one consideration is resistance management. That is, there are numerous companies using
[0234] Formulations and Other Delivery Systems. Formulated bait granules containing cells and/or proteins of the subject invention (including recombinant microbes comprising the genes described herein) can be applied to the soil. Formulated product can also be applied as a seed-coating or root treatment or total plant treatment at later stages of the crop cycle. Plant and soil treatments of cells may be employed as wettable powders, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.
[0235] As would be appreciated by a person skilled in the art, the pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about 10
[0236] The formulations can be applied to the environment of the pest, e.g., soil and foliage, by spraying, dusting, sprinkling, or the like.
[0237] Another delivery scheme is the incorporation of the genetic material of toxins into a baculovirus vector. Baculoviruses infect particular insect hosts, including those desirably targeted with the toxins. Infectious baculovirus harboring an expression construct for the toxins could be introduced into areas of insect infestation to thereby intoxicate or poison infected insects.
[0238] Insect viruses, or baculoviruses, are known to infect and adversely affect certain insects. The effect of the viruses on insects is slow, and viruses do not immediately stop the feeding of insects. Thus, viruses are not viewed as being optimal as insect pest control agents. However, combining the toxin genes into a baculovirus vector could provide an efficient way of transmitting the toxins. In addition, since different baculoviruses are specific to different insects, it may be possible to use a particular toxin to selectively target particularly damaging insect pests. A particularly useful vector for the toxins genes is the nuclear polyhedrosis virus. Transfer vectors using this virus have been described and are now the vectors of choice for transferring foreign genes into insects. The virus-toxin gene recombinant may be constructed in an orally transmissible form. Baculoviruses normally infect insect victims through the mid-gut intestinal mucosa. The toxin gene inserted behind a strong viral coat protein promoter would be expressed and should rapidly kill the infected insect.
[0239] In addition to an insect virus or baculovirus or transgenic plant delivery system for the protein toxins of the present invention, the proteins may be encapsulated using
[0240] Plant RNA viral based systems can also be used to express bacterial toxin. In so doing, the gene encoding a toxin can be inserted into the coat promoter region of a suitable plant virus which will infect the host plant of interest. The toxin can then be expressed thus providing protection of the plant from insect damage. Plant RNA viral based systems are described in U.S. Pat. No. 5,500,360 to Mycogen Plant Sciences, Inc. and U.S. Pat. Nos. 5,316,931 and 5,589,367 to Biosource Genetics Corp.
[0241] In addition to producing a transformed plant, there are other delivery systems where it may be desirable to engineer the bacterial gene(s). For example, a protein toxin can be constructed by fusing together a molecule attractive to insects as a food source with a toxin. After purification in the laboratory such a toxic agent with “built-in” bait could be packaged inside standard insect trap housings.
[0242] Mutants. Mutants of bacterial isolates can be made by procedures that are well known in the art. For example, asporogenous mutants can be obtained through ethylmethane sulfonate (EMS) mutagenesis of an isolate. The mutants can be made using ultraviolet light and nitrosoguanidine by procedures well known in the art.
[0243] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification.
[0244] Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
[0245] It was shown previously (U.S. Pat. No. 6,048,838) that
[0246] In summary, a 39,005 bp fragment of genomic DNA was obtained from strain Xwi and was cloned as cosmid pDAB2097. The sequence of the cosmid insert (SEQ ID NO. 6) was analyzed using the Vector NTI™ Suite (Informax, Inc. North Bethesda, Md., USA) to identify encoded ORFs (Open Reading Frames). Six full length ORFs and one partial ORF were identified (TABLE 4 ORFs identified in the pDAB2097 cosmid insert SEQ SEQ ORF ID NO. No. of ID NO. Desig- ORF Position in (Nucleo- Deduced (Amino nation SEQ ID NO. 13 tide) Amino Acids Acid) ORF1 1-1,533 7 511 8 ORF2 1,543-5,715 9 1,391 10 ORF3 5,764-7,707 11 648 12 ORF4 10,709-18,277 13 2,523 14 ORF5 18,383-21,430 15 1,016 16 (C*) ORF6 21,487-25,965 17 1,493 18 (C) ORF7 26,021-33,634 19 2,538 20 (C)
[0247] The nucleotide sequences of the identified ORFs and the deduced amino acid sequences encoded by these ORFs were used to search the databases at the National Center for Biotechnology Information by using BLASTn, BLASTp, and BLASTx, via the government (“.gov”) website of ncbi/nih for BLAST. These analyses showed that the ORFs identified in the pDAB2097 insert had significant amino acid sequence identity to genes previously identified in TABLE 5 Similarity of Deduced Proteins encoded by pDAB2097 ORFs to Known Genes % Amino Acid pDAB2097 ORF* Sequence (deduced amino Gene/ORF Designation Identity to acids) (GenBank Accession) Database Match ORF1 (1-511) tccA (AF047028) 21.4% ORF2 (313-1,391) xptD1 (AJ308438) 96.6% ORF3 (1-648) chi (AJ308438) 100% ORF4 (1-2,523) xptA1 (AJ308438) 99.5% ORF5 (1-1,016) xptB1 (AJ308438) 95.9% ORF6 (1-1,402) xptC1 (AJ308438) 96.4% ORF7 (1-2,538) xptA2 (AJ308438) 95.1%
[0248] Since ORF2, ORF4, ORF5, ORF6, and ORF7 were shown to have at least 95% amino acid sequence identity to previously identified genes, the same gene nomenclature was adopted for further studies on the ORFs identified in the pDAB2097 insert sequence (Table 6).
[0249] As used throughout this application, XptA2, for example, signifies a protein and xptA2, for example, signifies a gene. Furthermore, the source isolate for the gene and protein is indicated with subscript. An illustration of this appears in Table 6.
TABLE 6 Nomenclature of ORFs identified in pDAB2097 insert sequence PDAB2097 ORF Gene Designation ORF2 xptD1 ORF4 xptA1 ORF5 xptB1 ORF6 xptC1 ORF7 xptA2
[0250] A series of experiments was done in which
[0251] Two
[0252] Construction of pBT-TcdA. The expression plasmid pBT-TcdA is composed of the replication and antibiotic selection components of plasmid pBC KS+ (Stratagene) and the expression components (i.e. a strong
[0253] Construction of pBT-TcdA-TcdB. The TcdB1 coding sequence (GenBank Accession No. AF346500; reproduced here as SEQ ID NO:22) was amplified from plasmid pBC-AS4 (R. ffrench-Constant University of Wisconsin) using the forward primer:
5′ATATAGTCGACGAATTTTAATCTACTAGTAA (SEQ ID NO:23) AAAGGAGATAACCATGCAGAATTCACAAACATT CAGTGTTACC 3′.
[0254] This primer does not change the protein coding sequence and adds Sal I and Spe I sites in the 5′ non coding region. The reverse primer used was:
5′ATAATACGATCGTTTCTCGAGTCATTACACC (SEQ ID NO:24) AGCGCATCAGCGGCCGTATCATTCTC 3′.
[0255] Again, no changes were made to the protein coding sequence but an Xho I site was added to the 3′ non coding region. The amplified product was cloned into pCR2.1 (Invitrogen) and the DNA sequence was determined. Two changes from the predicted sequence were noted, a single A deletion in the Spe I site of the forward primer (eliminating the site) and an A-to-T substitution at corresponding amino acid position 1041 that resulted in the conservative substitution of Asp-to-Glu. Neither change was corrected. Plasmid pBT-TcdA was digested with Xho I and Pvu I (cutting at the 3′ end of the TcdA coding sequence). Plasmid pCR2.1-TcdB1was cut with Sal I and Pvu I. The fragments were ligated and pBT-TcdA-TcdB1recombinants (
[0256] Construction of pDAB3059. The coding sequence for the TccC1 protein (GenBank Accession No. AAC38630.1; reproduced here as SEQ ID NO:25) was amplified from a pBC KS+ vector (pTccC ch1; from R. ffrench-Constant, the University of Wisconsin) containing the three-gene Tcc operon. The forward primer was:
5′GTCGACGCACTACTAGTAAAAAGGAGATAA (SEQ ID NO:26) CCCCATGAGCCCGTCTGAGACTACTCTTTATAC TCAAACCCCAACAG 3′
[0257] This primer did not change the coding sequence of the tccC1 gene, but provided 5′ non coding Sal I and Spe I sites as well as a ribosome binding site and ATG initiation codon. The reverse primer was:
5′CGGCCGCAGTCCTCGAGTCAGATTAATTA (SEQ ID NO:27) CAAAGAAAAAACTCGTCGTGCGGCTCCC 3′
[0258] This primer also did not alter the tccC1 coding sequence, but provided 3′ Not I and Xho I cloning sites. Following amplification with components of an EPICENTRE FailSafe PCR kit (EPICENTRE; Madison, Wis.) the engineered TccC1 coding sequence was cloned into pCR2.1-TOPO (Invitrogen). The coding sequence was cut from pCR2.1 and transferred to a modified pET vector (Novagen; Madison Wis.) via the 5′ Sal I and 3′ Not I sites. The pET vector contains a gene conferring resistance to spectinomycin/streptomycin, and has a modified multiple cloning site. A PCR-induced mutation found via DNA sequencing was corrected using the pTccC ch1 plasmid DNA as template, and the plasmid containing the corrected coding region was named pDAB3059. Double-stranded DNA sequencing confirmed that the mutation had been corrected.
[0259] Construction of pBT-TcdA-TccC1. Plasmid pBT-TcdA DNA was cut with Xho I, and ligated to pDAB3059 DNA cut with Sal I and Xho I. The tccC1 gene was subsequently ligated downstream of the tcdA gene to create pBT-TcdA-TccC1 (
[0260] Construction of pBT-TcdA-TcdB1-TccC1. Plasmid pBT-TcdA-TcdB1 DNA was cut with Xho I and ligated to pDAB3059 DNA cut with Sal I and Xho I. Recombinants were screened for insertion of the tccC1 gene behind the tcdB gene to create plasmid pBT-TcdA-TcdB1-TccC1 (
[0261] Construction of pBT-TcdA-TcdB1-XptB1. Plasmid pBT-TcdA-TcdB1 DNA was cut with Xho I and shotgun ligated with pET280-XptB1DNA which was cut with Sal I and Xho I. Recombinants representing insertion of the xptB1 coding region into the Xho I site of pBT-TcdA-TcdB1 where identified to create plasmid pBT-TcdA-TcdB1-XptB1 (
[0262] Construction of pET28-TcdA. The description of this plasmid can be found elsewhere as Example 27 of WO 98/08932, Insecticidal Protein Toxins from
[0263] Construction of pCot-TcdB1. Plasmid pCR2. 1-TcdB1 was cut with Xho I and Sal I and ligated into the Sal I site of the T7 expression plasmid pCot-3 (
[0264] Construction of pCot-TccC1-TcdB1. The TccC1 coding region was cut from pDAB3059 DNA with Spe I and Not I and ligated into the multiple cloning site of plasmid pET280-K (a modified pET28 which has had the multiple cloning site replaced). This resulted in acquisition of a Swa I site upstream of the Spe I site and an Xho I site downstream of the Not I site. DNA of plasmid pET280-K-TccC1 was cut with Swa I and Xho I to release the TccC1 coding sequence, which was then ligated into the Swa I and Sal I sites of plasmid pCot-3-TcdB1 to create plasmid pCot-3-TccC1-TcdB (
[0265] Construction of pET280-XptA2, pET280-XptC1, and pET280-XptB1. The coding sequences for the XptA2, XptC1, and XptB1 proteins were each PCR amplified from pDAB2097, a recombinant cosmid containing the three genes that encode these proteins. The PCR primer sets used to amplify these coding sequences are listed in Table 7. In all of these primer sets, the forward primer did not change the coding sequence of the gene but provided 5′ non coding Sal I and Xba I sites as well as a ribosome binding site. The reverse primers also did not alter the corresponding coding sequences, but provided a 3′ Xho I cloning site. Following amplification with components of the EPICENTRE Fail Safe PCR kit, the engineered XptA2, XptC1, and XptB1 coding sequences were each cloned into pCR2.1. The cloned amplified products were sequence confirmed to ensure that PCR-induced mutations did not alter the coding sequences. Recombinant plasmids that contained unaltered coding sequences for XptA2, XptC1, and XptB1 were identified and designated as pDAB3056, pDAB3064, and pDAB3055, respectively. The coding sequences were each cut from the pCR2.1 derivatives and transferred to a modified pET vector (pET280-SS is a pET28 derivative which has had the multiple cloning site replaced, and a streptomycin/spectinomycin resistance gene inserted into the backbone to provide a selectable marker [TABLE 7 PCR Primers Used to Amplify XptA2, XptC1, and XptB1 Coding Sequences Coding Sequence Forward Primer Sequence Reverse Primer Sequence Amplified (5′-3′) (5′-3′) XptA2 GTCTAGACGTGCGTCGAC (SEQ ID NO:28) GCTCGAGATTAA (SEQ ID NO:29) AAGAAGGAGATATACC XptC1 GTCTAGACGTGCGTCGAC (SEQ ID NO:30) GACTCGAGAGCATTAA (SEQ ID NO:31) AAGAAGGAGATATACC XptB1 GTCTAGACGTGCGTCGAC (SEQ ID NO:32) GCTCGAGCAGATTAA (SEQ ID NO:33) AAGAAGGAGATATACC
[0266] Construction of pET280-XptA2-XptC1. Plasmid pET280-XptA2 DNA was cut with Xho I and ligated into the unique Sal I site in pDAB3064. The resulting ligated product contained both pCR2.1 and pET280-SS vector backbones and could be recovered by antibiotic selection using a combination of streptomycin (25 μg/mL), spectinomycin (25 μg/mL), and ampicillin (100 μg/mL). DNA of the recovered plasmids was digested with Xho I to check fragment orientation. A plasmid with the XptC1 coding region immediately downstream of the XptA2 coding region was obtained and the DNA was digested with Xho I to remove the pCR2.1 vector backbone. The resulting construct, which contains the pET280-SS vector backbone and the coding sequences for XptA2 and XptC1, was self-ligated to produce pET280-XptA2-XptC1.
[0267] Construction of pET280-XptC1-XptB1. Plasmid pET280-XptC1 DNA was cut with Xho I and ligated into the unique Sal I site in pDAB3055. The resulting ligated product contained both pCR2.1 and pET280-SS vector backbones and could be recovered by antibiotic selection using a combination of streptomycin (25 μg/mL), spectinomycin (25 μg/mL), and ampicillin (100 μg/mL). DNA of the recovered plasmids was digested with Xho I to check fragment orientation. A plasmid with the XptB1 coding region immediately downstream of the XptC1 coding region was obtained and the DNA was digested with Xho I to remove the pCR2.1 vector backbone. The resulting construct, which contains the pET280-SS vector backbone and the coding sequences for XptC1 XptB1, was self-ligated to produce pET280-XptC1-XptB1.
[0268] Construction of pET280-XptA2-XptB1. Plasmid pET280-XptA2 DNA was cut with Xho I and ligated into the unique Sal I site in pDAB3055. The resulting ligated product contained both pCR2.1 and pET280-SS vector backbones and could be recovered by antibiotic selection using a combination of streptomycin (25 μg/mL), spectinomycin (25 μg/mL), and ampicillin (100 μg/mL). DNA of the recovered plasmids was digested with Xho I to check fragment orientation. A plasmid with the XptB1 coding region immediately downstream of the XptA2 coding region was obtained and the DNA was digested with Xho I to remove the pCR2.1 vector backbone. The resulting construct, which contains the pET280-SS vector backbone and the coding sequences for XptA2 and XptB1, was self-ligated to produce pET280-XptA2-XptB1.
[0269] Construction of pET280-XptA2-XptC1-XptB1. Plasmid pET280-XptA2-XptC1 DNA was cut with Xho I and ligated into the unique Sal I site in pDAB3055. The resulting ligated product contained both pCR2.1 and pET280-SS vector backbones and could be recovered by antibiotic selection using a combination of streptomycin (25 μg/mL), spectinomycin (25 μg/mL), and ampicillin (100 μg/mL). The recovered plasmids were digested with Xho I to check fragment orientation. A plasmid with the XptB1 coding region immediately downstream of the XptC1 coding region was obtained and the DNA was digested with Xho I to remove the pCR2.1 vector backbone. The resulting construct, which contains the pET280-SS vector backbone and the XptA2,XptC1, and XptB1 coding sequences, was self-ligated to produce pET280-XptA2-XptC1-XptB1.
[0270] Expression of pBT-based constructions. The pBT expression plasmids were transformed into
[0271] Alternatively, the cells were chilled on ice after growth for 24 hours and adjusted to 20-30 OD
[0272] Expression of T7 Based Constructions. The T7 based expression plasmids were handled the same as the pBT expression plasmids described above, with the exception that they were transformed into the T7 expression strain BL21(DE3) (Novagen, Madison, Wis.), and a combination of streptomycin (25 μg/mL) and spectinomycin (25 μg/mL) was used for the antibiotic selection.
[0273] A series of expression experiments was performed using the pBT expression system as described above. TABLE 8 Bioassay of pBT-Expressed Complex Genes on Southern Corn Rootworm Experiment A. Day 1 Day 2 Plasmid 68 units/ml 68 units/ml pBT 0 0 pBT-TcdA 0 0 pBT-TcdA-TcdB1 0 0 pBT-TcdA-TccC1 0 0 pBT-TcdA-TcdB1-TccC1 ++++ +++++ Experiment B. Day 1 Day 2 Plasmid 85 units/ml 85 units/ml PBT 0 0 pBT-TcdA 0 0 pBT-TcdA-TcdB1 0 + pBT-TcdA-TccC1 0 0 pBT-TcdA-TcdB1-TccC1 ++++ +++++
[0274]
TABLE 9 Bioassay of pBT-Expressed Complex Genes on Southern Corn Rootworm Cells Lysate Frozen Lysate Plasmid 74 units/ml 10 mg/ml 10 mg/ml pBT 0 0 0 pBT-TcdA-TcdB1-TccC1 +++++ +++++ +++++
[0275] In another series of experiments, the TABLE 10 Bioassay of pBT Expressed Complex Genes on Southern Corn Rootworm Trial 1 Trial 2 Trial 3 Plasmid 110 units/ml 55 units/ml 111 units/ml pBT 0 0 0 pBT-TcdA-TcdB1-TccC1 +++ +++ +++ pBT-TcdA-TcdB1-XptB1 ++ ++ +++
[0276] Expression of the various TABLE 11 Bioassay of pCoT/pET (T7 promoter) Expressed Complex Genes on Southern Corn Rootworm Trial 1 Trial 2 Plasmids 40 units/ml 60 units/ml pCot/pET 0 0 pCot/pET-TcdA 0 0 pCot-TccC1-TcdB1/pET 0 0 pCot-TccC1-TcdB1/pET-TcdA +++ +++
[0277] Bioassay Results of Heterologously Expressed TABLE 12 Bioassay of Heterologously Expressed Complex Genes on TBW, CEW, and ECB TBW CEW ECB Plasmid Tested Bioassay Bioassay Bioassay pET-280 0* 0 0 pET-280-XptA2 +++ +++ ++ pET-280-XptC1 0 0 0 pET-280-XptB1 0 0 0 pET-280-XptA2-XptC1 + + 0 pET-280-XptA2-XptB1 0 0 0 pET-280-XptC1-XptB1 0 0 0 pET-280-XptA2-XptC1-XptB1 +++++ +++++ +++++
[0278] Bioassay results of heterologously expressed xptA2 tcdB1, and tccC1TABLE 13 Bioassay of Heterologously Expressed xptA2, tcdB1, and tccC1 on CEW Plasmids Tested CEW Bioassay pET280/pCoT 0* pET280/pCoT-TcdB1-TccC1 0 pCoT/pET280-XptA2 +++ pCoT/pET280-XptA2-XptC1-XptB1 +++++ pCoT-TcdB-TccC1/pET280-XptA2 +++++
[0279] This example provides additional data relating to co-pending U.S. provisional application serial No. 60/392,633, which is discussed in the Background section above. This data is relevant to the present application because it provides experimental evidence of the ability of
[0280] A. Co-Expression of DAS1529 TC Proteins and
[0281] Expression of the DAS1529 TC operon was regulated by T7 promoter/lac operator in the pET101.D expression vector that carries a ColE1 replication origin and an ampicillin resistance selection marker (Invitrogen). A comprehensive description of cloning and expression of the
[0282] For toxin production, 5 mL and 50 mL of LB medium containing antibiotics and 50 mM glucose were inoculated with overnight cultures growing on the LB agar plates. Cultures were grown at 30° C. on a shaker at 300 rpm. Once the culture density reached an O.D. of ˜0.4 at 600 nm, IPTG at a final concentration of 75 μM was added to the culture medium to induce gene expression. After 24 hours,
[0283] B. Bioassay for Insecticidal Activity
[0284] As described in Example 8 of U.S. Serial No. 60/392,633, DAS1529 TC ORFs, when expressed independently or as an operon, did not appear to be active against TBW and CEW. The following bioassay experiments focused on determining whether TABLE 14 Bioassay of DAS1529 TC potentiation of Insects: CEW Negative control − TCs (DAS1529) − XptA2 − TCs + XptA2 ++
[0285] For the second bioassay experiment, the amount of XptA2 protein in the XptA2 cells and the XptA2+TC operon cells was normalized based on densitometer gel scan analysis. As shown in Table 15, XptA2 per se had moderate activity at 40× on TBW (TABLE 15 Bioassay of IDAS1529 TC complementation of XptA2 on Normalized XptA2 40× 20× 10× 5× 2.5× 1.25× XptA2 + − − − n.d. n.d. TCs +XptA2 n.d. n.d. ++ ++ + −
[0286] The identification and isolation of genes encoding factors that potentiate or synergize the activity of the insect active proteins
[0287] The primary screen samples (in 96-well format) were tested in duplicate and scored compared to controls for insecticidal activity. Positive samples were re-grown and tested in the secondary screen. Cosmids identified as positive through primary and secondary screens were screened a third time. Larger culture volumes were utilized for tertiary screens (see below), tested for biological activity in a 128-well format bioassay.
[0288] DNA from one of the cosmids identified as having potentiating activity in this screen was subcloned. The DNA sequence of a single subclone which retained activity was determined and shown to contain two open reading frames, designated xptB1
[0289] Insect bioassays were conducted using artificial diets in either 96-well microtiter plates (Becton Dickinson and Company, Franklin Lakes, N.J.) or 128-well trays specifically designed for insect bioassays (C-D International, Pitman, N.J.). Eggs from 2
[0290] The data recorded in these bioassays included the total number of insects in the treatment, number of dead insects, the number of insects whose growth was stunted, and the weight of surviving insects. In cases where growth inhibition is reported, this was calculated as follows:
[0291] This is described in more detail in concurrently filed application by Apel-Birkhold et al., entitled “Toxin Complex Proteins and Genes from
[0292] Plasmid pDAB6026 was shown to encode activities which synergized the insect toxic activities of TcdA and XptA2TABLE 16 Response of 2 lepidopteran species to pDAB6026 lysates alone and with purified XptA2 tobacco budworm corn earworm Treatment Dead Stunted Total Weight Dead Stunted Total Weight 1 pBC 0 0 8 674 0 0 8 352 2 pBC + XptA2 0 0 8 538 0 0 8 423 3 pDAB6026 0 0 8 539 0 0 8 519 4 pDAB6026 + XptA2 0 8 8 18 8 — 8 —
[0293] DNA of plasmid pDAB6026 was sent to Seq Wright DNA Sequencing (Houston, Tex.) for DNA sequence determination. Two complete open reading frames (ORFs) of substantial size were discovered. The first (disclosed as SEQ ID NO:48) has significant similarity to known toxin complex genes belonging to the “B” class. This ORF was therefore called xptB1
[0294] The xptB1TABLE 17 Expression plasmids containing various coding regions cloned into the pET vector. Plasmid Name Coding Region Engineered for Expression pDAB6031 xptB1 pDAB6032 xptC1 pDAB6033 xptB1
[0295] Competent cells of the
[0296] The results of the bioassay are shown in Table 18. Control samples, which were not supplemented with low levels of added TcdA or XptA2TABLE 18 Response of coleopteran and lepidopteran species to proteins. Responses are presented as percent mortality/percent growth inhibition. Insect Species southern Lysates corn corn tobacco beet Sample Tested rootworm earworm budworm armyworm vector 0/0 8/0 0/0 31/0 pDAB6031 XptB1 0/0 0/0 0/0 31/33 pDAB6032 XptC1 0/0 4/11 0/2 13/15 pDAB6033 XptB1 0/0 0/0 0/6 13/38 Vector + TcdA 4/0 4/3 0/6 25/22 pDAB6031 + TcdA XptB1 0/0 0/0 0/5 13/34 pDAB6032 + TcdA XptC1 0/0 0/2 0/14 6/25 pDAB6033 + TcdA XptB1 25/68 4/14 4/0 31/48 Vector + XptA2 0/0 0/79 0/9 31/0 pDAB6031 + XptA2 XptB1 0/0 4/75 8/22 25/36 pDAB6032 + XptA2 XptC1 0/0 0/71 0/22 6/14 pDAB6033 + XptA2 XptB1 0/0 83/100 29/98 81/100
[0297] Bioassay driven fractionation of a pDAB6033-containing
[0298] Active fractions were identified based on their ability to synergize or potentiate the activity of TcdA against southern corn rootworm or XptA2
[0299] Two peaks of activity were detected from protein fractions eluting between 22-24 mS/cm conductance (Peak 1 and Peak 2). An example of the potentiating activity of Peaks 1 and 2 is shown in Table 19. Subsequent purification and analysis were performed on both Peak 1 and Peak 2
[0300] Gels from both Peak 1 and Peak 2 contained two predominant bands, one migrating at ˜170 kDa and the other migrating at ˜80 kDa. The gel from Peak 1 contained three additional proteins that migrated at approximately 18, 33 and 50 kDa. Retrospective analysis revealed that the ˜170 kDa and ˜80 kDa bands were abundant at the initial stages of purification and became progressively enriched at each step
[0301] Extracted peptides were analyzed using MALDI-TOF mass spectrometry to produce peptide mass fingerprints (PMF) on a Voyager DE-STR MALDI-TOF mass spectrometer (PerSeptive Biosystems, Framingham, Mass.). Analysis of the samples extracted from the ˜170 kDa band confirmed the identity as XptB1TABLE 19 Biological activity of purified Peak 1 and Peak 2 from pDAB6033. southern corn corn earworm rootworm Sample Dead Stunted Dead Stunted Peak 1 0 0 0 0 0 125 2 6 4 2 Peak 2 0 1 0 0 0 125 0 8 5 3
[0302] In this example, it is demonstrated that potent insect suppression is obtained with a combination of three toxin complex (TC) proteins. Compelling insect activity is observed when a Class A protein is mixed with a Class B and Class C protein. The present invention is surprising in that many combinations of a Class A, Class B and Class C protein result in powerful insect repression. The Toxin Complex proteins may be from widely divergent sources and may only share a limited amount of amino acid identity with other functional members of its class.
[0303] The insecticidal and growth inhibition activities encoded by fifteen different toxin complex genes were tested separately and in combination with one another. Several examples from each of the described classes, A, B or C, were tested. The genes were derived from three genera (
[0304] Surprisingly, the data below document the discovery that toxin complex Class A proteins may be mixed and matched with, for example, lysates prepared from
[0305] The Class A proteins TcdA and XptA2TABLE 20 Plasmid Class B Proteins Source Number TcdB1 pDAB8907 TcdB2 pDAB3089 TcaC pDAB8905 XptC1 pDAB8908 XptBl pDAB6031 PptB1 pDAB8722
[0306]
TABLE 21 Plasmid Class C Proteins Source Number TccC1 pDAB8913 TccC2 pDAB3118 TccC3 pDAB3090 TccC5 pDAB3119 XptBl pDAB8909 XptC1 pDAB6032 PptC1 pDAB8723
[0307]
TABLE 22A Plasmid Protein Combination Source Number TcdB1 + TccC1 pDAB8912 TcdB1 + TccC2 pDAB8712 TcdB1 + TccC3 pDAB3104 TcdB1 + TccC5 pDAB8718 TcdB1 + XptB1 pDAB8713
[0308]
TABLE 22B Plasmid Protein Number Combination Linker Sequence pDAB8912 TcdB1 + TccC1 tgactcgacgcactactagtaaaaaggagataacccc pDAB8712 TcdB1 + TccC2 tgactcgaatttaaattatatatatatatatactcgacgaattttaatctactagt aaaaaggagataacc pDAB3104 TcdB1 + TccC3 tgactcgacgcactactagtaaacaagaaggagatatacc pDAB8718 TcdB1 + TccC5 tgactcgaatttaaattatatatatatatatactcgacgaattttaatctactaga tttatttaaatttttttactagttttgtcgacaaaaaggagataacccc pDAB8713 TcdB1 + XptB1 tgactcgaatttaaattatatatatatatatactcgacaagaaggagatatacc
[0309]
TABLE 23A Plasmid Protein Combination Source Number TcdB2 + TccC1 pDAB3114 TcdB2 + TccC2 pDAB3115 TcdB2 + TccC3 pDAB3093 TcdB2 + TccC5 pDAB3106 TcdB2 + XptB1 pDAB3097 TcdB2 + XptC1 pDAB8910 TcdB2 + PptC1 pDAB8725
[0310]
TABLE 23B Plasmid Protein Number Combination Linker Sequence pDAB3114 TcdB2 + TccC1 ttaatctgactcgacgcactactagtaaaaaggagataacccc pDAB3115 TcdB2 + TccC2 ttaatctgactcgacgaattttaatctactagtaaaaaggagataacc pDAB3093 TcdB2 + TccC3 ttaatctgactcgacgcactactagtaaacaagaaggagatatacc pDAB3106 TcdB2 + TccC5 ttaatctgactcgacaaaaaggagataacccc pDAB3097 TcdB2 + XptB1 ttaatctgactcgacaagaaggagatatacc pDAB8910 TcdB2 + XptC1 ttaatctgactcgacaaaaaggagataaccccatgccttaaagaagagag agatatacc pDAB8725 TcdB2 + PptC1 ttaatctgactcgactttactagtaaggagatatacc
[0311]
TABLE 24 Plasmid Protein Combination Source Number TcaC + TccC1 pDAB8901 TcaC + TccC2 pDAB8902 TcaC + TccC3 pDAB8903 TcaC + TccC5 pDAB8904 TcaC + XptB1 pDAB8900 TcaC + XptCl pDAB8906
[0312]
TABLE 25 Plasmid Protein Combination Source Number XptC1 pDAB8914 XptC1 pDAB8915 XptC1 pDAB3103 XptC1 pDAB3105 XptC1 pDAB8916
[0313]
TABLE 26 Protein Plasmid Combination Source Number XptB1 pDAB8918 W-14 XptB1 pDAB6039 W-14 XptB1 pDAB6033 XptB1 pDAB8732
[0314]
TABLE 27 Protein Plasmid Combination Source Number PptB1 pDAB8724 PptB1 pDAB8726 str W-14 PptB1 pDAB8733 str W-14
[0315]
TABLE 28 Plasmid Protein Number Combination Linker Sequence pDAB8901 TcaC + TccC1 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatcgat ccgaattcgcccttgtcgacgcactactagtaaaaaggagataacccc pDAB8902 TcaC + TccC2 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatcaaa ttatatatatatatatactcgacgaattttaatctactagtaaaaaggagataacc pDAB8903 TcaC + TccC3 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatccga attcgagctccgtcgacgcactactagtaaacaagaaggagatatacc pDAB8904 TcaC + TccC5 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatcaaa tttttttactagttttgtcgacaaaaaggagataacccc pDAB8900 TcaC + XptB1 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatctcg atcccgcgaaattaatacgactcactataggggaattgtgagcggataacaatt cccctctagacgtgcgtcgacaagaaggagatatacc pDAB8906 TcaC + XptC1 taactcgatatggctagcatgactggtggacagcaaatgggtcgcggatccctt aaagaagagagagatatacc
[0316]
TABLE 29 Plasmid Protein Number Combination Linker Sequence pDAB8914 XptC1 ttaatgctctcgaatttgactagaaataattttgtttaactttaagaaggagata taccatgggcagcagccatcatcatcatcatcacagcagcggcctggtgc cgcgcggcagccatatggctagcatgactggtggacagcaaatgggtcg cggatccgaattcgcccttgtcgacgcactactagtaaaaaggagataacc cc pDAB8915 XptC1 ttaatgctctcgaatttgactagagtcgacgaattttaatctactagtaaaaag gagataacc pDAB3103 XptC1 ttaatgctctcgaatttgactagtcaaattatatatatatatatactcgacgcac tactagtaaacaagaaggagatatacc pDAB3105 XptC1 ttaatgctctcgaatttgactagatttatttaaatttttttactagttttgtcgacaa aaaggagataacccc pDAB8916 XptC1 ttaatgctctcgaatttgactagacgtgcgtcgacaagaaggagatatacc
[0317]
TABLE 30 Plasmid Protein Number Combination Linker Sequence pDAB8918 XptB1 ttaatgcggccgcaggaaatttttttgtcgactttactagtaaaaaggagat aacccc pDAB6039 XptB1 ttaatgcggccgcaggctagtaaacaagaaggagatatacc pDAB6033 XptB1 ttaatgcggccgcaggccttaaagaagagagagatatacc pDAB8732 XptB1 ttaatgcggccgcaggcctctgtaagactctcgactttactagtaaggaga tatacc
[0318]
TABLE 31 Plasmid Protein Number Combination Linker Sequence pDAB8724 PptB1 taatgtcgactttactagtaaggagatatacc pDAB8726 PptB1 taatgtcgactttactagtaaacaagaaggagatatacc pDAB8733 PptB1 taatgtcgactttactagtaaaaaggagataacccc
[0319] The pET expression plasmids listed in Tables 20-27 were transformed into the
[0320] Insect bioassays were conducted with neonate larvae on artificial diets in 128-well trays specifically designed for insect bioassays (C-D International, Pitman, N.J.). The species assayed were the southern corn rootworm,
[0321] Bioassays were incubated under controlled environmental conditions (28° C., ˜40% r.h., 16:8 [L:D]) for 5 days at which point the total number of insects in the treatment, the number of dead insects, and the weight of surviving insects were recorded. Percent mortality and percent growth inhibition were calculated for each treatment. Growth inhibition was calculated as follows:
[0322] In cases where the average weight of insects in treatment was greater that of insects in the vector only control, growth inhibition was scored as 0%.
[0323] The biological activity of the crude lysates alone or with added TcdA or XptA2
[0324] The results of bioassays are summarized in Tables 32-39. Little to no effect on the survival or growth of the insect species tested was observed when larvae were fed lysates from
[0325] Tables 32-39 show biological activity of TABLE 32 Biological activity of alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 Class B Genes tcdB1 0 + + 0 0 0 0 0 0 0 0 0 tcdB2 0 + 0 0 0 0 0 0 ++ 0 0 0 tcaC 0 0 0 0 0 0 0 0 0 0 0 0 xptC1 0 0 0 0 0 0 0 0 0 0 0 0 xptB1 0 0 0 0 0 0 0 0 + 0 0 0 pptB1 0 + 0 0 0 0 0 0 0 0 0 0
[0326]
TABLE 33 Biological activity of alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 Class C Genes tccC1 0 0 0 0 0 0 0 0 0 0 0 0 tccC2 0 0 0 0 0 0 0 0 0 0 0 0 tccC3 0 0 0 0 0 0 0 0 + 0 0 0 tccC5 0 0 0 0 0 0 0 0 0 0 0 0 xptB1 0 0 + 0 0 0 0 0 + 0 0 0 xptC1 0 0 0 0 0 0 0 0 + 0 0 0 pptC1 0 + 0 0 0 0 0 0 0 0 0 0
[0327]
TABLE 34 Biological activity of with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 TcdB1 Combinations tcdB1 + tccC1 0 + + 0 0 ++ 0 + +++ 0 0 0 tcdB1 + tccC2 0 0 0 0 0 0 0 0 + 0 0 0 tcdB1 + tccC3 0 ++ + 0 0 ++ 0 0 +++ 0 0 +++ tcdB1 + tccC5 0 + + 0 0 ++ 0 0 +++ 0 0 ++ tcdB1 + xptB1 0 0 0 0 0 ++ 0 0 ++ 0 0 ++
[0328]
TABLE 35 Biological activity of with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 tcdB2 Combinations tcdB2 + tccC3 0 +++ + 0 0 +++ 0 0 +++ 0 0 +++ tcdB2 + tccC5 0 +++ + 0 0 +++ 0 0 +++ 0 0 +++ tcdB2 + xptB1 0 + + 0 0 ++ 0 + +++ 0 0 + tcdB1 + xptC1 nt nt nt 0 0 + 0 0 +++ 0 0 + tcdB2 + pptC1 0 +++ + 0 0 + 0 0 ++ 0 0 +
[0329]
TABLE 36 Biological activity of with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 tcaC Combinations tcaC + tccC1 0 ++ + 0 0 ++ 0 0 +++ 0 0 +++ tcaC + tccC2 0 0 0 0 0 0 0 0 + 0 0 0 tcaC + tccCS 0 + + 0 0 ++ 0 0 +++ 0 0 ++ tcaC + tccC5 0 +++ + 0 0 ++ 0 0 ++ 0 0 +++ tcaC + xptB1 0 ++ 0 + + ++ 0 0 +++ 0 0 +++
[0330]
TABLE 37 Biological activity of with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 xptC1 Combinations xptC1 0 0 0 0 0 + 0 0 +++ 0 0 0 xptC1 0 0 0 0 0 0 0 0 + 0 0 0 xptC1 0 ++ + 0 0 ++ 0 0 +++ 0 0 ++ xptC1 0 ++ + 0 0 + 0 0 +++ 0 0 ++ xptC1 0 0 0 0 0 + 0 0 ++ 0 0 0
[0331]
TABLE 38 Biological activity of with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 xptB1 Combinations xptB1 nt nt nt 0 0 + 0 0 +++ 0 0 + xptB1 0 + 0 0 0 +++ 0 0 +++ 0 0 +++
[0332]
TABLE 39 Biological activity of combination with various Class C protein genes. Lysates were tested alone and with purified TcdA or XptA2 Insect Species southern corn rootworm tobacco budworm corn earworm beet armyworm Toxin Protein none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 none TcdA XptA2 pptB1 Combinations pptB1 0 +++ 0 0 0 ++ 0 0 +++ 0 0 + pptB1 0 +++ + 0 0 ++ 0 0 +++ 0 0 +++
[0333] To demonstrate the presently discovered versatility of TC proteins, additional
[0334] The T7 promoter based experiments were done by first preparing stocks of competent BL21(DE3) cells containing either pCot-3, pCot-TcdA or pCot-XptA2. These cells were then transformed with either control pET280 plasmid or any of the combinations of TC genes noted above in the pET280 vector. Cells containing both plasmids were selected on media containing chloramphenicol and kanamycin. Similarly, for the TABLE 40 Bioassay Results of Heterologously Expressed Toxin Complex Genes on TBW, SCR, ECB and BAW TBW SCR ECB BAW Bio- Bio- Bio- Bio- Sample Tested assay assay assay assay XptA2 ++ 0 ++ ++ TcdB1 0 0 + +++ XptC1 0 0 0 +++ TccC1 + 0 + +++ XptB1 0 0 0 +++ TcdB1 + TccC1 0 0 TcdB1 + XptB1 0 0 XptC1 + TccC1 0 0 XptC1 + XptB1 + 0 XptA2 + TcdB1 +++ + ++ XptA2 + XptC1 ++ 0 0 ++ XptA2 + TccC1 +++ + + +++ XptA2 + XptB1 +++ + 0 ++++ XptA2 + TcdB1 + TccC1 +++++ +++ +++++ XptA2 + TcdB1 + XptB1 +++++ +++ +++++ ++++ XptA2 + XptC1 + TccC1 ++++ 0 ++++ ++++ XptA2 + XptC1 + XptB1 ++++ + +++++ ++++ TcdA 0 +++ ++ 0 TcdA + TcdB1 0 +++ ++ 0 TcdA + XptC1 0 +++ ++++ 0 TcdA + TccC1 0 ++ 0 0 TcdA + XptB1 0 +++ ++ 0 TcdA + TcdB1 + TccC1 0 ++++ ++++ 0 TcdA + TcdB1 + XptB1 0 ++++ ++++ 0 TcdA + XptC1 + TccC1 0 ++++ ++ 0 TcdA + XptC1 + XptB1 0 +++ ++++ 0
[0335]
TABLE 41 Bioassay of Heterologously Expressed Toxin Complex Genes on SCR, TBW, CEW, and FAW with the addition of purified TcdA Toxin Protein* SCR TBW CEW FAW Plasmid Tested Bioassay Bioassay Bioassay Bioassay pET-280 0 0 0 0 pET-280-TcdB1-XptB1 ++++ + ++ 0 pET-280-TcdB2-TccC3 +++++ + 0 ++
[0336]
TABLE 42 Bioassay of Heterologously Expressed Toxin Complex Genes on SCR, TBW, CEW, and FAW with the addition of purified XptA2 Toxin Protein* SCR TBW CEW FAW Plasmid Tested Bioassay Bioassay Bioassay Bioassay pET-280 0 + +++ 0 pET-280-TcdB1-XptB1 ++++ +++++ +++++ +++ pET-280-TcdB2-TccC3 ++++ +++++ +++++ ++++
[0337] The following Tables summarize and compare proteins used in the assays described above. Tables 43-45 compare A, B, and C class proteins. Tables 46-48 compare A, B, and C class genes (bacterial). Any of the numbers in these tables can be used as upper and/or lower limits for defining proteins and polynucleotides for use according to the subject invention. Table 49 compares the sizes of various TC proteins. Again, any of the numbers in this table can be used to define the upper and/or lower size limits of proteins (and polynucleotides) for use according to the subject invention.
[0338] These tables help to show that even highly divergent proteins (in the ˜40-75% identity range) can surprisingly be used and substituted for each other according to the subject invention. TcdA2TABLE 43 TcdA TcdA2 TcdA4 TcbA XptA1 XptA2 SepA % % % % % % % % % % % % % % Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- ity tity ity tity ity tity ity tity ity tity ity tity ity tity TcdA 100.0 100.0 61.3 55.0 74.3 68.0 61.4 50.1 57.3 46.3 53.8 40.6 52.6 40.7 TcdA2 100.0 100.0 63.7 55.9 52.7 42.4 52.3 41.3 48.3 36.8 45.5 34.7 TcdA4 100.0 100.0 59.0 49.4 54.8 44.4 51.7 38.7 50.6 38.7 TcbA 100.0 100.0 54.7 43.7 54.0 40.8 52.8 40.2 XptA1 100.0 100.0 57.6 44.2 57.7 46.6 XptA2 100.0 100.0 50.7 38.2 SepA 100.0 100.0 Tested in Mix yes no no yes no yes no & Match Assays? Does it yes NA NA yes NA yes NA work?
[0339]
TABLE 44 TcdB1 TcdB2 TcaC XptC1 XptB1 PptB1 (Orf5) SepB % % % % % % % % % % % % % % Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- Similar- Iden- ity tity ity tity ity tity ity tity ity tity ity tity ity tity TcdB1 100.0 100.0 79.9 75.6 69.5 58.2 61.3 50.2 65.6 54.6 55.3 42.3 63.7 52.6 TcdB2 100.0 100.0 68.1 57.2 60.7 49.8 65.6 53.3 54.2 42.0 61.7 51.4 TcaC 100.0 100.0 63.9 51.6 70.6 59.8 56.9 42.6 61.4 50.1 XptC1 100.0 100.0 65.2 53.2 53.9 40.7 58.1 47.8 XptB1 100.0 100.0 54.2 40.6 57.4 46.0 PptB1 (Orf5) 100.0 100.0 51.5 38.7 SepB 100.0 100.0 Tested in Mix & yes yes yes yes yes yes no Match assays? Does it work? yes yes yes yes yes yes NA
[0340]
TABLE 45 TccC1 TccC2 TccC3 TccC4 TccC5 % % Id % % Id % % Id % % Id % % Id Sim. Sim. Sim. Sim. Sim. TccC1 100.0 100.0 57.8 48.1 62.0 52.8 62.5 52.9 59.7 51.3 TccC2 100.0 100.0 60.3 52.5 62.2 53.7 67.9 61.4 TccC3 100.0 100.0 65.4 59.5 66.0 58.4 TccC4 100.0 100.0 64.8 57.2 TccC5 100.0 100.0 XptB1 XptC1 PptC1 (Orf6 long) PptC1 (Orf6 short) SepC Tested in yes yes yes no yes Mix & Match assays? Does it work? yes no yes NA yes XptB1 XptC1 PptC1 PptC1 SepC (Orf6 (Orf6 long) short) % % Id % % Id % % Id % % Id % % Id Sim. Sim. Sim. Sim. Sim. TccC1 59.0 45.5 55.8 46.5 45.0 35.0 45.9 35.7 56.0 44.1 TccC2 54.0 44.1 56.4 47.2 46.5 35.3 45.7 36.1 55.8 46.1 TccC3 54.8 46.0 56.5 48.1 45.1 35.4 46.1 36.1 56.4 46.6 TccC4 53.6 44.8 58.8 49.1 46.3 36.9 47.3 37.7 56.6 45.3 TccC5 55.1 45.6 57.6 48.7 45.3 35.2 46.3 36.0 54.8 44.9 XptB1 100.0 100.0 52.6 41.4 43.3 32.7 44.3 33.5 55.2 46.3 XptC1 100.0 100.0 46.4 35.4 47.4 36.2 53.0 43.5 PptC1 (Orf6 long) 100.0 100.0 97.6 97.6 45.1 34.9 PptC1 (Orf6 short) 100.0 100.0 46.2 35.7 SepC 100.0 100.0 Tested in yes yes yes current no Mix & Match testing assays? Does it work? yes yes yes ? NA
[0341]
TABLE 46 tcdA tcdA2 tcdA4 tcbA xptAl xptA2 sepA % Identity % Identity % Identity % Identity % Identity % Identity % Identity tcdA 100.0 65.3 70.6 58.2 56.8 54.4 53.1 tcdA2 100.0 64.5 56.2 55.9 53.3 51.9 tcdA4 100.0 57.8 55.6 52.5 51.7 tcbA 100.0 56.3 54.0 52.7 xptA1 100.0 55.8 55.4 xptA2 100.0 53.8 sepA 100.0 Tested in Mix & Match yes no no yes no yes no Assays? Does it work? yes NA NA yes NA yes NA
[0342]
TABLE 47 tcdB1 tcdB2 tcaC xptC1 xptB1 pptB1 (Orf5) sepB % Identity % Identity % Identity % Identity % Identity % Identity % Identity tcdB1 100.0 74.1 62.3 44.7 59.7 52.3 57.6 tcdB2 100.0 61.5 44.7 59.6 52.6 57.1 TcaC 100.0 46.0 62.0 52.5 55.3 xptC1 100.0 44.9 44.9 44.5 xptB1 100.0 52.3 54.7 pptB1 (Orf5) 100.0 52.5 sepB 100.0 Tested in Mix & Match yes yes yes yes yes yes no assays? Does it work? yes yes yes yes yes yes NA
[0343]
TABLE 48 PptC1 (Orf6 PptC1 (Orf6 TccC1 TccC2 TccC3 TccC4 TccC5 XptB1 XptC1 long) short) SepC % Identity % Identity % Identity % Identity % Identity % Identity % Identity % Identity % Identity % Identity TccC1 100.0 55.7 58.8 60.0 59.4 45.0 55.7 47.5 48.4 54.3 TccC2 100.0 62.6 62.2 69.9 43.5 58.1 51.6 52.4 55.4 TccC3 100.0 65.7 66.4 44.9 58.4 51.5 52.4 56.8 TccC4 100.0 65.8 43.0 59.4 52.2 53.2 54.9 TccC5 100.0 43.0 58.5 50.8 51.7 56.2 XptB1 100.0 44.6 43.6 43.2 44.0 XptC1 100.0 49.7 50.6 54.5 PptC1 (Orf6 long) 100.0 97.6 50.6 PptC1 (Orf6 short) 100.0 51.8 SepC 100.0 Tested in Mix & Match yes yes yes no yes yes yes yes in progress no assays? Does it work? yes no yes NA yes yes yes yes ? NA
[0344]
TABLE 49 DNA Bases Protein Amino Acids Protein Daltons Functional? tcdA 7548 2516 282,932 yes tcdA2 7497 2499 283,725 ? tcdA4 7143 2381 270,397 ? tcbA 7512 2504 280,632 yes xptA1 7569 2523 286,799 ? xptA2 7614 2538 284,108 yes SepA 7128 2376 262,631 ? Range 7128-7614 2376-2538 262,631-286,799 tcdB1 4428 1476 165,127 yes tcdB2 4422 1474 166,326 yes TcaC 4455 1485 166,153 yes xptC1 4479 1493 168,076 yes xptB1 4518 1506 168,635 yes pptB1 (Orf5) 4332 1444 161,708 yes SepB 4284 1428 156,539 ? Range 4284-4518 1428-1506 156,539-168,635 TccC1 3129 1043 111,686 yes TccC2 2745 915 103,398 no TccC3 2880 960 107,054 yes TccC4 2847 949 106,563 ? TccC5 2814 938 105,106 yes XptB1 3048 1016 111,037 yes XptC1 2886 962 107,960 yes PptC1 (Orf6 long) 2859 953 109,130 yes PptC1 (Orf6 short) 2790 930 106,244 ? SepC 2919 973 107,020 ? Range 2745-3129 915-1043 103,398-111,686
[0345]